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ABSTRACT 
Over the last five decades, allogeneic hematopoietic stem cell transplantation (HSCT) has 
evolved rapidly, continuing to offer a cure for several hematological diseases. Nevertheless, 
associated life-threatening complications remain an obstacle against exploiting its full 
therapeutic benefit. Among these complications, infection, relapse, and graft-versus-host disease 
(GVHD) represent not only the most common but also the most serious ones. Though 
commonly regarded as distinct clinical events, their underlying pathophysiology is firmly 
related from an immunological perspective. 
T lymphocytes are key players in HSCT complications and their proper reconstitution following 
allogeneic HSCT is central for beneficial clinical outcome. The last two decades have witnessed 
a growing interest in a subset of T cells known as gamma delta (γδ) T cells. The immunological 
capabilities of these unconventional cells have been intensively explored. However, more efforts 
aimed at unraveling the immunobiological features of different γδ subsets are warranted to 
effectively exploit their full immunotherapeutic potential. 
In the present work, I tried to tackle several immune-related aspects that directly influence 
allogeneic HSCT outcome with a special focus on γδ T cells. In paper I, the main objective was 
to address the impact of different GVHD prophylaxis regimens on de novo generation of T and 
B lymphocytes. Using PCR methods, T cell receptor recombination excision circle (TREC), 
kappa deleting recombination excision circle (KREC), and telomere length (TL) were quantified 
in the peripheral blood (PB) of transplanted patients at several time intervals. Although there 
was no significant difference between the two GVHD prophylaxis groups, we identified other 
transplant related factors that were associated with reduced TREC and/or KREC levels after 
HSCT. Furthermore, we showed that high levels of these excision circles correlated with 
favorable outcome post HSCT. 
In paper II-IV, more attention was paid to explore the role of γδ T cells in donor grafts. Using 
multicolor flow cytometry together with other molecular and functional assays, we found a 
significant association between graft frequencies of CD8+γδ T cells and acute GVHD (aGVHD) 
grade II-III in Paper II. Additionally, we showed that higher frequencies of CD27+ γδ T cells in 
the stem cell grafts were correlated with both less relapse and CMV incidences. 
The results from paper II highlighting a potential role of CD8+γδ T cells in donor grafts raised 
our interest to further investigate this subset to elucidate their immunological characteristics. In 
paper III we thoroughly analysed γδ T cells in BM grafts using multicolor flow cytometry and 
TCR repertoire analysis using next generation sequencing (NGS). We showed that grafts from 
CMV+ donors contained higher proportions of CD8+γδ T that preferentially expressed Vγ9- 
and differentiated towards terminal effector memory phenotype. Additionally, analysis of TCRγ 
chain revealed a clonally focused repertoire in CMV+ donor grafts. We also showed that 
CD8+γδ T cells differentially respond to TCR stimuli suggesting adaptive-like phenotype 
In paper IV, we sought to address whether allogeneic HSCT outcome is influenced by γδ TCR 
repertoire composition in donor grafts. Immunosequencing of TCRγ chain by NGS revealed a 
more public repertoire and increased presence of long sequence clonotypes in graft given to 
non-relapsed patients. Further analysis of the amino acid sequences identified 12 public and 4 
private sequences that were exclusively found in high frequencies in grafts given to non-
relapsed patients. 
Finally, in paper V we aimed to optimize a protocol for efficient in-vitro expansion of Vγ9Vδ2 
T cells from umbilical cord blood (UCB). Phenotypical and functional characterization of 
expanded cells was comparable to PB and suggests that UCB can be a reliable source for 
Vγ9Vδ2 T cell expansion.    
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1 INTRODUCTION 
1.1 ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION 
1.1.1 Background 
Allogeneic hematopoietic stem cell transplantation (HSCT) is a well-established yet complex 
treatment for a variety of disorders of the hematopoietic system (Figure 1) (1). In principle, 
allogeneic HSCT is preceded by cytoreductive conditioning regimen, that aims at reducing 
malignant burden, avoiding graft rejection, and enhancing engraftment. The stem cell (SC) 
graft is then infused from a suitable donor selected based on human leukocyte antigen (HLA) 
matching. The SC grafts can be obtained from bone marrow (BM) or from peripheral blood 
(PBSC) after mobilization by G-CSF or plerixafor. Umbilical cord blood (UCB) units can also 
be used as graft source (2, 3). 
Initially, allogeneic HSCT was limited to few indications such as acute leukemia, severe 
aplastic anemia (SAA), or severe combined immunodeficiency (SCID). The remarkable 
progress in HSCT as a consequence of the advancement in transplant technique and better 
understanding of the human immune system has led to a progressive increase in the number of 
HSCTs performed to a level that, in just half a century, over 1 million HSCTs were performed 
worldwide, of which about 40 % were allogeneic HSCTs (4). The current practice of HSCT is 
rapidly evolving and guidelines are continuously updated and modified reflecting the 
complexity of this procedure. 
 
Figure 1. Illustration of the process of allogeneic HSCT. 
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Despite major improvements in allogeneic HSCT, it is still hampered by the associated 
complications which represent a major cause of morbidity and mortality among transplanted 
patients (5). These complications are due to several elements such as conditioning regimen 
associated toxicities, prolonged immune deficiency, and organ and tissue damage. Among 
these complications, graft-versus-host disease (GVHD) remains a major leading cause of non-
relapse mortality following allogeneic HSCT (6). Since GVHD is a central outcome in my 
thesis (papers I, II, and IV), in the next section, I will discuss in more detail the 
pathophysiology and underlying immune mechanisms implicated in GVHD 
1.1.2 Graft-Versus-Host Disease  
Graft-versus-host disease (GVHD) is an unfavorable immune response mounted by donor 
immune cells that recognize recipient cells as foreign, resulting in organ and tissue damage 
(7). GVHD is a frequent event following allogeneic HSCT. It has been estimated that around 
50 % of allogeneic HSCT patients develop some degree of GVHD (8). Morbidities caused by 
GVHD are due to several factors including organ/tissue damage, immune suppression due to 
the prolonged use of immunosuppressive drugs with the resulting increased risk of infection 
(9). 
Despite the major advancements in the field, little progress has been achieved in GVHD 
treatment rendering it one of the leading causes of transplant-related morbidities and 
mortalities. GVHD is classically seen in both an acute and chronic form, with symptoms 
ranging from mild to devastating organ damage (10).  
1.1.2.1 Acute GVHD 
Acute GVHD (aGVHD) is the second leading cause of death after relapse in allogeneic HSCT 
patients. The main target organs involved are skin, intestine, and liver. aGVHD is classed into 
IV grades, with grade I indicating mild disease and grade IV for very severe disease (11). 
Disparity of human leukocyte antigen (HLA) between donor and recipient is a common 
genetic trigger and is associated with increased risk of aGVHD(12). Nevertheless, not all HLA 
mismatches induce severe GVHD as some of these mismatches (permissive mismatches) are 
not associated with severe aGVHD (3, 9). Besides HLA allele mismatches, other peptide 
products of polymorphic genes, known as minor histocompatibility antigens (miHAgs), can be 
recognized by donor T cells as alloantigens and can initiate aGVHD. Multiple studies 
indicated that miHAgs encoded by the Y chromosome are significantly associated with severe 
aGVHD in male recipients that received allografts from female donors (13, 14). 
Other non-genetic risk factors for GVHD include graft source, intensity of conditioning 
regimen, and age (15). While the role of stem cell source has been thoroughly investigated, the 
impact of conditioning regimen is still controversial. In this regard, several clinical studies 
showed increased risk and severity of GVHD, particularly cGVHD in patients receiving 
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PBSC as graft source compared to BM grafts. Moreover, co-morbidities prior to allogeneic 
HSCT are associated with GVHD incidence and severity (6). 
The pathophysiology of aGVHD is classically described in two main stages: an initial 
inflammatory stage and an effector stage (Figure 2) (6). The inflammatory process is 
commonly initiated by trigger molecules in the extracellular matrix. Several endogenous 
molecules such as ATP, uric acid, High-mobility group box-1 (HGMB1), and heparan sulfate 
are known as danger-associated molecular patterns (DAMPs). These DAMPs are released in 
response to tissue damage and, thus, induce sterile inflammation (7). Alternatively, 
inflammation can be initiated by exogenous pathogenic components of microbes and bacteria 
that translocate through damaged intestinal mucosa or skin. These molecules are known as 
pathogen-associated molecular patterns (PAMPs) and include lipopolysaccharides and 
bacterial RNA or DNA molecules (16). 
Both DAMPs and PAMPs serve as ligands for pattern recognition receptors (PRR) expressed 
by innate immune cells and professional antigen presenting cells (APCs) such as monocytes, 
dendritic cells, and macrophages. Once APCs are activated by these danger molecules, they 
upregulate HLA molecules and other costimulatory molecules necessary for T cell priming 
(17).  
Another crucial event during this phase is the secretion of soluble pro-inflammatory 
mediators. The classical cytokines involved in aGVHD include the IL-1B, IL-6, and TNFα. 
Other cytokines such as IL-17 and IL-23 have been also described (18). These pro-
inflammatory cytokines are pivotal for the inflammatory process and facilitate the recruitment 
of other immune cells (19). 
Microbiota have also been involved in the pathophysiology of GVHD, particularly intestinal 
GVHD, in a way that involves various delicate homeostatic mechanisms (20). Paneth cells, 
present in the intestinal mucosa, secrete antimicrobial peptides that maintain microbiome 
homeostasis (21). Pro-inflammatory cytokines induce damage to Paneth cells resulting in 
dysbiosis. Alternatively, recent evidence showed that microbiota-derived metabolites are 
important for the regeneration of intestinal stem cells (ISCs) which are crucial for the integrity 
of the intestinal barrier (22). Additionally, gut microbiota can secrete butyrate that modulates 
immune cell response through indolamine-2,3-dioxygenase dependent mechanism. The use of 
broad-spectrum antibiotics was associated with severe GVHD probably due to dysregulation 
of the microbiota (23, 24).  
The effector stage is initiated when donor T cells encounter alloantigens/mismatched HLA 
presented by host APCs. This results in activation and proliferation of donor T cells which, in 
turn, secrete inflammatory cytokines such as IL-2, TNFα and IFNγ further aggravating tissue 
damage (25). In contrast to host APCs, the role of donor APCs in GVHD is still unclear.  
Host tissue damage in aGVHD can be mediated by CD4 or CD8 donor T cells (26). A key 
difference is that CD8 T cells require direct interaction with cognate antigen/HLA class I 
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complex on host tissue, whereas CD4 T cells can mediate tissue damage through cytokine 
release without requiring direct cognate recognition (7, 27). 
 
 
Figure 2. Immunological mechanisms in acute GVHD. (Reproduced with permission from Zeiser R et al. (11), 
Copyright Massachusetts Medical Society). 
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1.1.2.2 Chronic GVHD  
Chronic GVHD (cGVHD) is also a common complication after allogeneic HSCT, with an 
incidence ranging between 30-70% (28). cGVHD is distinguished by aberrant tissue repair 
with characteristic formation of fibrosis. Patients developing cGVHD are at higher risk of 
long-term morbidity and low quality of life after allogeneic HSCT (29).  The clinical features 
of cGVHD are heterogenous reflecting the involvement of different organ systems with 
pleiotropic manifestations. According to the 2014 National institute of health (NIH) consensus 
criteria (30), cGVHD is graded into mild, moderate, and severe (Table 1). This classification 
was based on a scoring system that assesses the severity of disease for each of the involved 
organs (skin, oral, ocular, GIT, genital, liver, lung, fascia, and joints). Several risk factors for 
cGVHD have been reported including, prior aGVHD, HLA mismatch, female donor for a 
male recipient, older age, high-intensity conditioning, and chronic myeloid leukemia (31) 
cGVHD stage Score  
Mild < 3 Organs involved with score 1 (Lung score 0) 
Moderate  >=3 organs involved with score 1. OR At least 1 organ (not lung) with 
a score of 2 OR Lung score 1 
Severe  At least 1 organ with a score 3. OR Lung score of 2 or 3 
  
Table 1. Scoring system for chronic GVHD 
Unlike aGVHD, the underpinning immune mechanisms of cGVHD is less understood and 
represents a complex interaction of several immune mechanisms. Recent studies in mice 
models have been crucial for establishing many of these underlying mechanisms. 
The pathophysiology of cGVHD can be divided into 3 stages (Figure 3) (28). The first is the 
inflammatory stage which like aGVHD is initiated by DAMPS and PAMPS, released 
extracellularly as a result of tissue damage or as a component of microbial pathogens. The net 
result is the activation of the innate immune system and release of soluble pro-inflammatory 
mediators. Th17 cells have been implicated as they are induced to differentiate by IL-1β and 
IL-6 and can maintain inflammatory state through IL-17 (32, 33). Additionally, neutrophils 
can amplify tissue damage and inflammation through reactive oxygen species (ROS) and 
inflammasomes (34). Furthermore, APCs become activated and upregulate their HLA 
molecules, facilitating the activation of adaptive immune cells. 
The next stage involves the activation of adaptive lymphocytes by APCs. In addition to T 
cells, B cell hyper-responsiveness and impaired immunoglobulin response occurs in cGVHD 
(35). Additionally, injury of cortical and medullary thymic epithelial cells (cTEC and mTEC) 
by conditioning drugs or as a result of aGVHD, leads to impaired central tolerance allowing 
export of autoreactive T cells to the circulation, further aggravating disease severity (36). 
Besides central tolerance, peripheral tolerance is also compromised as both T regulatory 
(Treg) and B regulatory (Breg) cells are dysfunctional or deficient in cGVHD patients (37). 
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The third stage is manifested by abnormal tissue repair. This has been attributed to the 
activation of fibroblasts by macrophages through TGFβ and PDGFα, the result of which is 
excess release of extracellular matrix collagen (38). 
 
Figure 3. Immunological phases of chronic GVHD. (Reproduced with permission from Zeiser R et al. (28), 
Copyright Massachusetts Medical Society). 
1.1.2.3 GVHD biomarkers 
Several research efforts have been directed towards identifying reliable biomarkers for GVHD 
(39, 40). Biomarkers would allow early diagnosis before clinical signs and could be useful 
prognostic markers for the risk of GVHD progression and unresponsiveness to therapy (41). A 
reliable biomarker should be able to differentiate between GVHD and other inflammatory 
conditions. It should also be non-invasive and easily performed (simple) as well as 
inexpensive. Some of these biomarkers are summarized in table 2 
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Biomarker  Significance  Notes and references 
Ratio of Treg: effector T cells Associated with GVHD (42, 43) 
High serum level of IL-4, -6, -8, -
-10, -17, TNFα 
Proinflammatory cytokines 
increased in the serum of 
GVHD patients 
Can increase in other 
inflammatory conditions (41) 
Elafin  Skin specific (44) 
REG3α Gut specific (39) 
ST2, CXCL9, matrix 
metalloproteinase 3, osteopontin 
Correlated with cGVHD 
severity 
Can be used for risk 
assessment (45) 
Serum levels of miRNAs 
(miRNA-155, miRNA 146) 
Associated with aGVHD (46) 
SNPs in CCR5, CCR6, FGFR1, 
CTLA4 genes 
Association with cGVHD Requires further validation in 
multi-center cohorts (47, 48) 
   
Table 2. Biomarkers for GVHD. 
1.1.2.4 Role of T cells and other immune cells in GVHD  
Donor-derived T cells are substantial in the pathogenesis of GVHD. That said, they also 
mediate beneficial effects. The alloreactive response between donor-derived lymphocytes and 
neoplastic cells is known as the graft-versus-leukemia (GVL) or graft-versus-tumor (GVT) 
reaction and represents a cornerstone for the effective eradication of malignant cells in 
allogeneic HSCT (49). The GVL effect is the basis for the immunotherapeutic effect of 
allogeneic HSCT, offering a survival advantage for patients with malignant disorders (50). 
The dual face of alloreactive T cells has also been shown in the clinical setting. It was noticed 
that the risk of relapse after allogeneic HSCT was lower in patients who developed cGVHD 
compared to those who did not show any symptoms of GVHD (51-53). Furthermore, 
induction of GVHD by tapering immunosuppression has been shown to re-establish remission 
in leukemic relapse after allogeneic HSCT (54-56). It is worth mentioning that both GVHD 
and GVT responses are virtually absent in transplantations with grafts fully depleted of T cells 
(57). 
Unlike donor memory T cells, naïve T cells plays a substantial role in GVHD initiation (58). 
This has been attributed to their abundant expression of CD62L and CCR7, allowing homing 
of naïve T cells to secondary lymphoid organs where they can be primed and activated by 
APCs. Additionally, naïve T cells possess higher T cell antigen receptor (TCR) repertoire 
diversity compared to memory cells. This feature could explain their ability to recognize a 
broader spectrum of alloantigens (59, 60). 
B cells also have a significant role, particularly in cGVHD.  By acting as professional APCs, 
as well as their ability to produce cytokines such as IL-21, they can facilitate T cell activation 
(61). Additionally, it has been demonstrated that rituximab (anti-CD20) containing 
conditioning regimen was associated with a reduced rate of GVHD (62). Conversely, B 
regulatory cells can improve GVHD severity in an IL-10 dependent manner (63).   
Natural killer (NK) cells, like other effector cells, have been implicated in GVHD 
pathophysiology, though they are less likely involved in the direct GVHD initiation (64). In 
fact, clinical studies have shown that higher NK cell doses in allografts were associated with 
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less severe aGVHD, most probably due to the elimination of host APCs by donor NK cells 
(65). 
1.1.2.5 GVHD Prophylactic and Therapeutic strategies 
Most current prophylactic protocols center on suppression of alloreactive donor T cells (9). 
The standard GVHD prophylactic approach that is currently used in most HSCT recipients 
comprises a calcineurin inhibitor; cyclosporine A (CsA) or tacrolimus (Tac) combined with 
methotrexate (Mtx), a folate antagonist. Alternative regimens that include the use of 
mammalian target of rapamycin (mTOR) inhibitor such as sirolimus (Sir) instead of Mtx, have 
been used yet without superior advantages over the standard regimen (66). 
Post-HSCT cyclophosphamide has been shown to selectively deplete proliferating alloreactive 
T cells with minimal or no effect on stem and Treg cells, probably because of the high 
expression of aldehyde dehydrogenase by these cells (67). This approach has permitted 
transplantation across major HLA barriers. In this regard, clinical studies have reported less 
severe GVHD in haploidentical transplants that received post-transplant cyclophosphamide 
(68). 
Other novel pharmacological agents that act through targeting specific signaling pathways are 
currently under investigation in preclinical studies or clinical trials and could hold promise to 
treat GVHD in the future. Recently, Ibrutinib, a novel drug that targets the burton’s tyrosine 
kinase (BTK) pathway, has been approved by FDA for the treatment of glucocorticoid-
resistant cGVHD patients (28). The mechanisms of actions of these drugs are illustrated in 
figure 4. 
In addition to current pharmacological drugs, cell-based therapies have been extensively 
investigated. Donor T cell depletion in allografts has been associated with less severe GVHD. 
T cell depletion can be achieved either through ex vivo manipulation of allografts (e.g. CD34+ 
positive selection, CD3+ depletion, αβ depletion) or in vivo, using neutralizing anti-T cell 
antibodies. While this approach remarkably reduced the incidence of GVHD, it is hampered 
by the associated increased risk of relapse, infections, and slower immune reconstitution (69). 
Another cell-based approach is based on inducing peripheral tolerance. Multiple studies 
investigated the use of Treg cells to treat GVHD. Mesenchymal stromal cells (MSC) have 
been also investigated with promising results especially in steroid refractory GVHD. 
Importantly, the progress in HLA-typing has significantly improved outcome by reducing 
GVHD incidence and severity, while increasing the rate of engraftment (70-72). 
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Figure 4.  The mechanism of actions of classical and emerging drugs for GVHD prophylaxis Reproduced with 
permission from Zeiser R et al. (28), Copyright Massachusetts Medical Society). 
1.2 T CELL RECONSTITUTION FOLLOWING ALLOGENEIC HSCT 
Allogeneic HSCT is associated with a critical period of immune deficiency, predisposing 
patients to increased susceptibility of severe life-threatening bacterial, viral, and fungal 
infections. Therefore, efficient restoration of functional immune system is substantial for 
beneficial outcome (73).  
The innate immune system recovers earlier during the first weeks following HSCT, providing 
essential protection against bacterial infection. The first innate cells to recover are monocytes, 
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followed by neutrophils (74). Regeneration of damaged mucosal barrier provides additional 
protection against pathogen penetration. Neutrophil engraftment is defined clinically as the 
first day of three successive days with absolute neutrophil count > 0.5 ×109 cells/L. The time 
to engraftment is critical and varies between patients depending on several factors. It has been 
shown that neutrophils reach normal levels earlier in HSCT using Peripheral Blood (PB) 
compared to Bone marrow (BM) as graft source, while UCB is associated with prolonged 
time to engraftment (75). Since T cells are more relevant to my thesis, in the following section 
I will discuss different aspects related to T cell reconstitution following allogeneic HSCT. 
1.2.1 Human Thymus: an overview 
The development of the human thymus starts early in fetal life from the endoderm of the third 
and fourth pharyngeal pouches. By the 7th gestational week, stem cells populate the thymus 
which continues to descend until it reaches its final position in the superior mediastinum 
above the heart (76). Structurally, the thymus consists of bilateral lobes enclosed in 
mesenchymal capsule. The thymic parenchyma consists of an outer cortex and an inner 
medulla, together comprising the niche essential for supporting proper maturation of 
thymocytes (77). 
The biological role of the thymus remained among the most intriguing mysteries in the history 
of medicine for decades until its immunological role was first discovered by J.F Miller in the 
early 60s (78). Within the thymus, T cell progenitors undergo multi-differentiation steps and 
phenotypic changes, ultimately leading to the generation of a diverse repertoire of self-tolerant 
naïve T cells (Figure 5). These steps entail complex interactions between T cell precursors and 
both thymic epithelial cells (TECs) and dendritic cells (DCs). 
The rearrangement of the T cell antigen receptor (TCR) takes place in the thymus through 
somatic recombination of their variable (V), (diversity (D)), and joining (J) gene segments. 
This complex process is mediated by recombinase activating genes and is pivotal to generate a 
diverse repertoire of T cells, allowing recognition of a wide range of pathogens (79). 
As a result of the randomly generated TCRs, some autoreactive clones are produced. Thus, a 
stringent process comprised of two consecutive selection steps is implemented to eliminate 
autoreactive clones. In the first step, thymocytes at the double-positive (DP) stage are tested 
for the ability of their TCR to recognize peptide/MHC complexes expressed by cTECs in a 
process referred to as positive selection. T lymphocytes that successfully recognize 
peptide/MHC complexes survive and differentiate into CD4+ or CD8+ single positive 
thymocytes (80). 
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Figure 5. The process of thymocyte development in the thymus. (reproduced with permission from Krenger et al. (81)) 
Thymocytes upregulate CCR7 expression which allows them to migrate to the thymic medulla 
where the second stage takes place. Within the thymic medulla, clonal deletion of autoreactive 
T cells occurs in a process referred to as negative selection (77). Medullary thymic epithelial 
cells (mTECs) provide the microenvironment essential for negative selection. The 
transcription factor autoimmune regulator (Aire) and more recently described Fezf2 that 
regulate the expression of a large set of self-antigens including the tissue-restricted antigens 
(TRA) are selectively expressed by mTECs (80). 
1.2.2 Reconstitution of T lymphocytes: two distinct pathways 
The clinical outcome following allogeneic HSCT relies to large extent on optimal T cell 
reconstitution. Following allogeneic HSCT, the recovery of the T cell pool is accomplished 
through two distinct processes; A) thymic-independent homeostatic proliferation of donor-
derived mature T cells, and B) thymic-dependent de novo generation of naïve T cells from 
donor HSCs (Figure 6) (74, 77, 82). In fact, in HSCT settings where donor T cells are 
intentionally depleted, the thymus represents the main source for T cell generation (83). 
Though the thymic-independent pathway is a short track for rapid replenishment of the 
virtually empty T cell pool, the extent to which it contributes to protection against infection is 
rather limited due to skewing of the TCR repertoire (84, 85). In this case, the TCR diversity 
depends on the initial diversity state of the donor-derived T cells in the SC graft (81). 
Additionally, T cells undergoing homeostatic proliferation are more prone to activation-
induced cell death (86). Moreover, donor-derived T cells are potentially alloreactive, which 
can be beneficial through exerting a potent GVL effect, but also can be harmful as it has been 
associated with the development of GVHD (87). On the other hand, thymic-generated T cells 
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undergo TCR rearrangement and stringent selection steps resulting in a self-tolerant, highly 
diverse repertoire of T cells (82, 88). 
 
Figure 6. Reconstitution of T cells through thymic and extrathymic pathways. 
1.3 GAMMA DELTA (γδ) T CELLS 
1.3.1 Background 
Gamma delta (γδ) T cells are unconventional T lymphocytes that express T cell antigen 
receptor (TCR) formed of γ and δ chains (89). Alongside B cells and αβ T cells, γδ T cells co-
evolved in vertebrates for several million years and have been implicated in anti-microbial and 
anti-tumoral immune surveillance (90). 
The proportion of γδ T cells varies depending on the type of tissue. While accounting for 1-
10% of T lymphocytes in the peripheral blood of an adult human, they usually constitute 10-
70% of resident T cells in other tissue compartments such as skin, intestinal mucosa, and the 
female reproductive system (91). In contrast to αβ T cells, most γδ T cells do not express 
CD4/CD8 co-receptors. Additionally, γδ T cells can be activated in both TCR-dependent and 
independent manners, acting as a bridge between innate and adaptive immunity (92).  
1.3.2 Subsets of human γδ T cells 
Though γδ T cells have co-evolved in rodents and mammals, human γδ T cells orthologically 
differ from their mouse counterparts due to evolutionary divergence of the γ and δ loci 
between the two species. While the γ chain is used to classify murine γδ T cells (e.g γ1, γ4, γ5, 
etc...), human γδ T cells are basically defined by their δ chain. Accordingly, human γδ T cells 
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can be grouped into two major subsets Vδ2+ subset and Vδ2- subset of which Vδ1+ cells are 
the predominant fraction (93). 
1.3.2.1 Vδ2+ subset  
In adults, γδ T cells expressing a semi-invariant TCR comprised of Vδ2 and Vγ9 domains 
(Vγ9Vδ2) are the predominant subset in peripheral blood (50-95% of γδ T cells) and are 
characterized by their reactivity to phosphoantigens (PAgs) (94, 95). 
Vγ9Vδ2 T cells play a pivotal role in lymphoid immune stress surveillance. Their ability to 
recognize infected or transformed cells through a TCR-independent or TCR-dependent but 
HLA-unrestricted manner (Figure 7), has placed these cells in the first line of defense (96). 
The Vγ9Vδ2 TCR can recognize a group of nonpeptidic phosphorylated antigens known as 
phosphoantigens (PAgs). These antigens can be produced endogenously as intermediates of 
the isoprenoid biosynthesis of the mevalonate pathway (e.g. isopentenyl pyrophosphate (IPP)), 
or exogenously, such as HMBPP produced by the microbial non mevalonate pathway (97). Of 
note, IPP is less potent than HMBPP and its physiological levels are below the activation 
threshold of Vγ9Vδ2 cells. Noteworthy, in tumor cells, the mevalonate pathway is upregulated 
resulting in accumulation of IPP, thus acting as a tumor-associated antigen (93).  
Additionally, Vγ9Vδ2 T cells can recognize cells under stress, such as transformed or infected 
cells, through TCR-independent mechanisms. Besides pattern recognition receptors (98), 
Vγ9Vδ2 T cells are equipped with other receptors such as natural killer group 2 D (NKG2D) 
and DNAX accessory molecule 1 (DNAM1) receptors (89). The ligands of NKG2D receptors 
comprise the stress‐inducible ligands MHC class I-related chain A/B (MICA/B) and UL16 
binding protein (ULBP). These ligands are upregulated in transformed and stressed cells, 
allowing rapid recognition and elimination by Vγ9Vδ2 T cells (99). 
Furthermore, Vγ9Vδ2 T cells express CD16, a low affinity receptor that can bind the constant 
region of immunoglobulin (FcγIII). Thus, they can mediate recognition and killing of 
opsonized target cells through antibody dependent cellular cytotoxicity (ADCC) without need 
for TCR engagement (100). 
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Figure 7. Tumor cell recognition by Vγ9Vδ2 T cells 
1.3.2.2 Vδ2- subset 
Vδ2- γδ T cells are dominated by a subset that express a TCR that contains a δ chain variable 
region 1 paired with various γ chains, known as Vδ1+ T cells and represent approximately 
50% of γδ T cells in fetal blood. However, in adults they are predominantly found in epithelial 
tissues (101). Vδ1+ T cells can effectively eradicate tumor cells and display potent anti-viral 
response especially against CMV after transplantation. 
In contrast to Vγ9Vδ2 T cells, Vδ1 TCRs recognize a wider range of antigens (Figure 8), 
including lipid antigens presented by MHC-like molecules, CD1c and CD1d (101). 
Additionally, MICA/B have been suggested as ligands for TCR of Vδ1+ cells, though 
NKG2D affinity to MICA/B was shown to be 1000-fold higher compared to TCR (102). 
In addition to NKG2D and DNAM1 mediated recognition, Vδ1+ cells activated in vitro 
through the TCR can express natural cytotoxicity receptors such as NKp30 and NKp44. 
Moreover, downregulation of HLA class I as tumor immune evasion mechanism can enhance 
the cytotoxicity of Vδ1+ cells through activation of killer inhibitory receptors (KIR).  
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Figure 8. Tumor cell recognition by Vδ1 T cells 
1.3.3 γδ TCR repertoire and ligands 
T cells including γδ T cells differentiate from a common T cell progenitor in the thymus, 
where poorly defined mechanisms involving complex signaling pathways drives their lineage 
commitment (αβ or γδ) (101). However, unlike αβ T cells, antigen recognition by γδ TCR is 
fundamentally different in that it is major histocompatibility complex (MHC) unrestricted. 
Furthermore, the CDR3 length pattern of the δ chain is more analogous to that of antibodies 
than the conventional TCRs (103, 104). 
Both γ and δ chains are encoded by two distinct sets of genes. The TRD locus is located on 
chromosome 14, embedded within the TRA gene, whereas TRG is found on chromosome 7 
(105). An essential prerequisite for γδ T cell development and lineage commitment is the 
formation of a functional TCR. This entails somatic recombination of the variable (V), 
diversity (D), and joining (J) gene segments in the TRD locus and the V and J segments in the 
TRG locus. In theory, somatic recombination of the γδ TCR can yield up to 1017 possible 
unique clones, resulting in extensive diversity. Nevertheless, circulating γδ T cells are 
dominated by cells that express a semi-invariant TCR formed of Vγ9Vδ2, suggesting the 
potential of early neonatal exposure to PAgs that shapes the repertoire of γδ T cells throughout 
life (106). 
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Next generation sequencing (NGS) has enabled in-depth analysis of CDR3 of TCR δ and γ 
repertoires. Studies have indicated that the TCR δ repertoire is more diverse yet comprises 
highly private (less public) CDR3 sequences. Contrastingly, TCR γ repertoire displays limited 
diversity and contains CDR3 sequences that are commonly shared among individuals (public) 
(107). 
Furthermore, the TCR repertoire displays fundamental differences between different subsets. 
While the TCR repertoire of Vδ1+ cells is initially highly diverse at birth and becomes more 
focused at adulthood. The repertoire of Vγ9Vδ2 T cells has intermediate diversity and does 
not considerably differ between adults and cord blood (Figure 9) (108).  
The semi-invariant nature of Vγ9Vδ2 TCR has been further elucidated through exploring the 
γ9 repertoire. CDR3 sequences of γ9 are enriched in public amino acid sequences that persist 
throughout life. This has been attributed to the presence of multiple germ line encoded 
sequences with limited junctional diversity beside the effect of convergent recombination. 
The responsiveness of Vγ9Vδ2 cells to PAgs has also been linked to the TCR molecular 
structure. The exclusive pairing of Vγ9 to JγP but not to other Jγ families, has been shown to 
mediate PAgs recognition. Likewise, CDR3 of δ2 is enriched in hydrophobic amino acid 
residues at position 5 that are crucial for PAgs recognition. 
 
Figure 9. TCR repertoire of Vδ1 and Vδ2Vγ9 cells at birth and adulthood.  
γδ TCR ligands are under extensive ongoing research. Immunotherapeutic strategies using γδ 
T cells have been hindered by poor understanding of the mode of TCR mediated antigen 
recognition (109). Thus, identifying such ligands would be of utmost importance to unleash 
the full immunological capabilities of γδ T cells and overcome the current limitations to 
  17 
exploiting γδ T cells in immunotherapeutic strategies. Furthermore, distinguishing a specific 
ligand for a certain γδ clone could allow in vitro clonal expansion in a large clinical scale 
sufficient for use in adoptive immunotherapy. 
The earliest defined antigens for γδ T cells are PAgs that specifically induce activation and 
proliferation of Vγ9Vδ2 T cells. Though Vγ9Vδ2 responsiveness to PAgs had been 
discovered in early 90s, their underpinning recognition mechanism remains unknown. Large 
body of evidence suggests a member of the B7 super family, BTN3A1, to function as an 
antigen presenting molecule though its exact mode of recognition remains elusive (110). In 
one model, BTN3A1 was proposed to capture and present PAgs directly to Vγ9Vδ2 TCR 
(111). More recently, this model was challenged by results from other groups supporting an 
inside-out signaling model where PAgs bind an intracellular domain of BTN3A1, known as 
B30.2. this binding induces conformational changes in the extracellular domain and results in 
TCR activation (112, 113). Sebestyen and colleagues, proposed a model that involves RhoB 
intrinsic GTPase activity. Suggesting that RhoB relocalizes to BTN3A1, inducing cytoskeletal 
changes which in turn stabilize BTN3A1 molecules and allows for subsequent PAgs binding 
(110). 
In contrast to Vγ9Vδ2 T cells the ligands for Vδ2- cells have remained elusive. Several efforts 
have been made to identify some ligands. Multiple studies have reported some potential 
ligands (Table 3). However, these ligands are heterogenous with regards to their structure and 
biology. Their exact mode of recognition remains elusive, adding more complexity to the 
already confusing landscape. 
Ligand name Cells that recognize location  reference 
BTN3A Vγ9Vδ2 PB Salim et al. (114) 
BTNL3-BTNL8 Vγ4Vδ1 Intestinal γδ cells Melandri et al. (115) 
EPCR Vγ4Vδ5 PB Willcox et al. (116) 
Annexin A2 Vγ8Vδ3 -- Marlin et al. (117) 
phycoerythrin Vδ1 PB Zeng et al. (118) 
CD1c Vδ1 PB Roy et al. (119) 
CD1d Vδ1 PB Uldrich et al. (120) 
MICA/B Vδ1 PB Xu et al. (102) 
Table 3. γδ TCR ligands 
1.3.4 Adaptive-like γδ T cells 
The hallmark of the adaptive immune response is manifested by the ability of cells to display 
clonal selection and expansion upon recognition of cognate antigen concurrently with the 
differentiation from a naïve to an effector/memory phenotype. With this concept in mind, 
several researchers have explored the adaptive immunobiology of γδ T cells (121, 122).  
γδ T cells have been widely considered as innate-like. Similar to mucosal associated invariant 
T (MAIT) cells and invariant natural killer T (iNKT) cells, the predominant γδ cells in the PB 
display a semi-invariant TCR (Vγ9Vδ2), that features limited diversity and responds to a 
limited antigen (pAgs) in the context of presenting molecule (BTN3A1). In this paradigm, 
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TCR can be considered as surrogate pattern recognition receptor. Furthermore, the ability of 
Vγ9Vδ2 cells to react rapidly in response to stress-induced signals in a non TCR-dependent 
way supports innate-like paradigm (121). 
Davey et al, used NGS and single TCR sequencing to explore the TCR repertoire of Vδ1+ 
cells. They revealed that Vδ1+ TCR repertoire is initially diverse at birth and become highly 
focused in adulthood. Furthermore, they explored Vδ1+ TCR repertoire perturbation in 
response to CMV infection. They revealed significant clonal expansion, suggesting that Vδ1+ 
cells respond to a driving antigen (CMV) by clonotypic expansion of a few clones. 
Furthermore, clonality was associated with differentiation from naïve-like (CD27 high) to 
effector (CD27 low) phenotype (108). 
In another study, Davey et al showed that Vδ2+ cells comprise two clonotypically and 
biologically distinct subsets. An innate-like population that expresses Vγ9+Vδ2+ TCR and 
respond to PAgs and another small subset that preferentially pairs to non Vγ9 (Vγ9-Vδ2+). 
Unlike its Vγ9+ counterpart, this subset was unresponsive to PAgs yet responded to TCR 
stimuli. Furthermore, they displayed clonal expansion in response to CMV infection 
suggesting adaptive-like biology (122). 
1.3.5 Functional diversity of γδ T cells 
While murine γδ T cells acquire their functional effector phenotype early during thymic 
development, human γδ T cells exit the thymus as naïve cells and acquire their functional fate 
in the periphery. Noteworthy, unlike their mouse counterparts, human γδ T cells are by default 
programmed to be cytotoxic effector cells that secrete IFNγ and TNFα, thus they have anti-
tumorous protective function by nature. However, in presence of highly inflammatory milieu 
as tumor microenvironment, γδ T cells can undergo reprogramming and acquire IL-17 
producing phenotype (IL-17 γδ T cells) (109). 
It has been shown that γδ T cells can differentiate into IL-17 producing cells in response to 
certain cytokines such as IL-1β, IL-23, IL-6 and TGFβ. These cytokines are characteristically 
heightened in the inflammatory tumor microenvironment as a result of their increased 
secretion by macrophages and myeloid cells in the tumor microenvironment. Furthermore, it 
has been shown that microbiota induce IL-17 γδ T cells, which explains the increased 
proportions of IL-17 γδ T cells in cases of severe meningitis (99). 
The pro-tumorous function of IL-17 γδ T cells has been established in mice and human 
studies, where the presence of IL-17 γδ T cells in higher frequencies was found to be 
associated with increased tumor growth and metastasis (93). 
Mechanistic analysis highlighted several underlying mechanisms that mediate the pathogenic 
effect of IL-17 γδ T cells (Figure 10); 1- IL-17 produced mainly by IL-17 γδ T cells in tumor 
microenvironment can act directly on IL-17 receptors expressed by some tumors and induce 
their growth. 2- IL-17 can induce angiogenesis through upregulating pro-angiogenic factors 
such as vascular endothelial growth factor (VEGF). 3- A reciprocal cross talk between IL-17 
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γδ T cells and myeloid cells has been described. IL-17 γδ T cells have been shown to induce 
G-CSF mediated neutrophil and macrophage mobilization to tumor microenvironment and 
have been shown to induce neutrophil differentiation into myeloid derived suppressive cells 
(MDSC) that exert strong suppressive effect on other T cells (123). 4- Through the secretion 
of the cytokine IL-4 and the expression of programmed cell death protein ligand 1 (PDL-1), 
IL-17 γδ T cells can exert direct suppressive effect on other T cells. 5- IL-22 produced by IL-
17 γδ T cells has been shown to induce tumor cell proliferation (93, 99, 109). 
 
Figure 10. Pro-tumor role of IL-17γδ T cells 
1.3.6 γδ T cells in allogeneic HSCT 
The antitumor property of γδ T cells has been shown for the first time by Heyday’s group in 
experimental mice model (124).  It has soon become well established that γδ T cells can 
exhibit potent anti-tumor/anti-viral immune responses in the absence of an alloreactive 
immune response. This feature has placed γδ T cells as a subject of great interest in allogeneic 
HSCT as they can offer the beneficial GVL effect in the absence of GVHD. 
1.3.6.1 Reconstitution following allogeneic HSCT 
In contrast to conventional αβ T cells and B cells, γδ T cell recovery occurs shortly after 
HSCT (125). Hirokawa et al. examined reconstitution of γδ TCR repertoire after allogeneic 
HSCT. They reported that the γδ TCR repertoire was almost completely recovered a few 
months after transplantation (126). Although the reconstitution of γδ T cells has been 
investigated to some degree, the effect of different transplant related factors, such as donor 
type, conditioning regiment etc. on frequency and TCR diversity remains largely unknown. 
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The effect of G-CSF mobilization on γδ T cells are controversial. Bian et al. examined 
phenotypic characteristics of γδ T cells in the peripheral blood of 20 donors before and after 
G-CSF mobilization. They showed that γδ T cells retained their homeostatic proportions and 
IFN-γ secreting capabilities following G-CSF (127). Conversely, earlier study showed that G-
CSF was associated with TCR repertoire disturbances in the form of alteration of distribution 
and clonality of some TRG and TRD subfamilies, suggesting a potential immune modulatory 
effect (128). 
Numerus studies have highlighted the importance of conventional αβ T cell recovery after 
HSCT, but the impact of γδ T cell recovery has not been well described. In this regard, early 
reconstitution of γδ T cells has been correlated with favorable outcome after allogeneic HSCT. 
It has been confirmed in multiple clinical studies that patients with elevated γδ T cells 
numbers have increased leukemia-free survival and overall survival (129, 130). Perko et al. 
investigated the recovery of γδ T cells in 102 pediatric patients with acute leukemia after 
allogeneic HSCT. They reported decreased incidence of infection and improved event-free 
survival in patients with elevated γδ T cells (131). 
1.3.6.2 Anti-tumor effect 
The role of γδ T cells in tumor surveillance was first demonstrated in a mouse model where 
mice without γδ T cells were found to be more susceptible to the development of cutaneous 
malignancy (124). Since then, numerous studies have corroborated and extended these 
findings in different tumor models (132-135). The anti-tumor effector functions can be 
mediated by direct cytotoxicity or indirectly through the production of cytokines/chemokines 
by which they affect other cell types. Additionally, γδ T cells can upregulate surface 
expression of Fc-receptor FcRγIII (CD16) which can be implicated in tumor cell lysis via 
antibody-dependent cellular cytotoxicity (ADCC) (92, 105). 
In human cancer, the presence of infiltrating γδ T cells has been found in a large range of 
different tumor types. In a recent large meta-analysis of expression signatures from 18000 
human tumor samples covering 39 different tumor, γδ T cell signature was found to be the 
most favorable significant cancer-wide prognostic immune cell population (136). 
1.3.6.3 Anti-infectious properties of γδ T cells 
The ability of γδ T cells to protect against infectious pathogens is mediated by several 
mechanisms. Cytotoxic activities can be mediated by Fas-Fas ligand interaction, 
perforin/granzyme release, and CD16 mediated ADCC (125).  Additionally, γδ T cells can 
interact with and modulate the activity of other immune cells. For instance, they can promote 
DC maturation and enhance anti-infectious activities of NK and macrophage. Furthermore, γδ 
T cells can secrete large amounts of pro-inflammatory cytokines such as IFN-γ, TNFα, IL-17, 
and IL-22 (90). 
In allogeneic HSCT, the anti-bacterial role of γδ T cells is not well displayed. This is due to 
the administration of prophylactic antibiotics which effectively control bacterial infection. The 
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anti-viral role is more prominent. CMV reactivation has been shown to be associated with 
expansion of Vδ2- T cells (137, 138). Furthermore, several studies have highlighted the role of 
Vδ1 T cells in CMV reactivation after allogeneic HSCT (137, 139). De Paoli et al. showed a 
possible role of γδ T cells in EBV immune response (140). 
1.3.6.4 γδ T cells and GVHD 
whether γδ T cells are implicated in immunopathology of GVHD remained an open question. 
Most evidence indicated that donor γδ T cells are not key effectors in inducing GVHD and 
their levels in PB following HSCT were not associated to increased severity or incidence of 
GVHD (92, 125, 135, 141).  However, few studies in murine models have shown that γδ T 
cells contribute to pathogenesis of GVHD (142-144). Maeda et al, investigated the role of host 
γδ T cells in experimental GVHD model using γδ deficient and wild type mice. They showed 
mechanistically that host γδ T cells exacerbate GVHD by enhancing the alloreactive capacity 
of DCs through cell contact dependent manner (144).  
Given the early reconstitution of γδ T cells during HSCT, investigating graft composition of 
γδ T cells can provide insight into their contribution to clinical outcome, particularly aGVHD 
following HSCT. In this context, Pabst et al. showed increased cumulative incidence of acute 
GVHD II-IV in patients that received PBSC grafts with higher γδ T cells content (145). 
However, they examined total γδ T cells and the impact of different subsets were not 
investigated. Given the heterogeneity of γδ T cells (146, 147), more research is needed in 
order to elucidate the role of different γδ T cell subsets in GVHD. 
1.3.7 γδ T cells as an attractive target for immunotherapy 
The ability of γδ T cells to produce large amounts of cytokines, expression of perforin, 
granzymes, and death receptor ligands, as well as their ability to bypass tumor immune 
evasion mechanisms based on MHC class I down regulation, has made them an attractive 
target for cancer immunotherapy (97). However, the potential to use γδ T cells for adoptive 
cell therapy (ACT) was challenged by their scarcity in PB. Moreover, the standard methods of 
T cell culture can induce apoptosis in γδ T cells (92, 148). Fortunately, this obstacle was 
overcome with the discovery that aminobisphosphonate drugs can specifically induce 
activation and expansion of Vγ9Vδ2 T cells by inhibiting a key enzyme (farnesyl PP synthase) 
in the mevalonate pathway, leading to accumulation of PAgs (97). 
In fact, expansion of γδ T cells from adult PB has been explored with considerable success. 
For this purpose, two main strategies have been widely used in adoptive cell therapy. In vivo 
Expansion of γδ T cells could be achieved by the administration of bisphosphonates such as 
zoledronate (Zol). It has been shown that this method not only can expand cells but also 
increase their lytic function (149, 150). However, it has been reported that γδ T cells rapidly 
exhaust upon repeated application of Zol (146). In vitro techniques involve the stimulation of 
γδ T cells with natural or synthetic PAgs in presence of exogenous cytokines. More efficient 
expansion could be achieved following the use of autologous dendritic cells pretreated with 
Zol (150, 151). Furthermore, the use of anti-apoptotic cytokines, like IL-15, has been reported 
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to prevent activation-induced cell death of in vitro cultured γδ T cells (150, 152). The adoptive 
transfer of Vδ2 T cells expanded in vitro appeared to be well tolerated with no major adverse 
effects.  
 Clinical trials using ex vivo expanded PB γδ T cells for immunotherapy have been confirmed 
to be safe and have shown adequate results in patients with malignancies such as renal cell 
carcinoma (153), melanoma (154), and multiple myeloma (155). Other clinical trials have 
explored treatment of patients with γδ T cells expanded in vivo by bisphosphonates and IL-2 
(156, 157). Despite these trials, no large-scale studies with long term follow-up exist to our 
knowledge. 
In contrast to Vγ9Vδ2 T cells, Vδ1 T cells have not received the same attention until recently. 
several reports have indicated that Vδ1 T cells exhibit more potent cancer killing and express 
higher levels of CD69, CD107a, granzyme B, TRAIL, and HLA-DR than Vδ2 T cells (158). 
While Vγ9Vδ2 T cells have been successfully expanded, there are only few attempts for Vδ1 
expansion. Lamb et al. used an approach based on αβ T cell depletion from PBMC and using 
irradiated leukemia feeder cells and low levels of IL-2 (135). Using phytohemagglutinin 
(PHA) and IL-7, Wu et al. selectively expanded Vδ1 T cells from PB of healthy donors as 
well as colon cancer patients(158). More recently, Almeida et al. developed a protocol for 
selective enrichment and expansion of delta one T (DOT) cells (159). In their protocol, Vδ1 
cells were stimulated and differentiated by using TCR agonists in presence of IL-4 and IL-15. 
The expanded DOT cells by this protocol were functionally active and were able to target 
acute myeloid leukemia via NKp30 (160).  
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2 AIMS 
The hypothesis of my thesis is that γδ T cells specifically attack malignant cells without 
causing detrimental GVHD in patients after HSCT. We postulate that their development is 
closely related to whether patients will relapse in their malignant disease.  
The results from this work would help to increase patient survival and decrease 
transplantation-associated complications such as malignant relapse and infectious 
complications. It will also make it possible for more patients eligible for HSCT 
The general aim of my doctoral research project is to investigate the role of the adaptive 
immune system, with a special focus on γδ T cells, in allogenic HSCT. 
More specifically, in paper I we investigated de novo generation of lymphocytes post 
allogeneic HSCT and addressed whether thymopoiesis and B cell neogenesis are affected by 
GVHD prophylaxis regimens and their role in predicting clinical outcome.  
In papers II-IV, we sought to investigate the graft composition of γδ T cells in detail and 
addressed whether γδ T cell phenotype/TCR repertoire is correlated to clinical outcome in 
terms of malignant relapse, viral/bacterial infections and other complications. 
Finally, in paper V, we aimed to develop and improve a protocol for γδ T cell expansion from 
UCB. We then studied the phenotypic and functional properties of expanded cells for future 
use in adoptive cell immunotherapy. 
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3 MATERIALS AND METHODS 
3.1 SAMPLE CHARACTERISTICS 
In my thesis, different sample types were used. In paper I, PB samples were collected from 
transplanted patients at several time points following allogeneic HSCT. In total 200 patients, 
with at least one retrievable blood sample were included. Characteristics of patients are 
shown in table 4 
Variable CsA/Mtx Tac/Sir 
   
Number of patients 103 97 
Median age, years (range) 53 (0.6‒71) 51 (2.8‒68) 
Number of children <18 years 12  13  
Sex, number of males/females  57/46  63/34  
Median follow-up, years (range) 7.6 (3.9‒10.3) 7.2 (3.9‒10.3) 
Diagnosis, number of patients:   
     AML/ALL 27/19 22/22 
     CLL 7 15 
     Lymphoma 14  13 
     MDS 19 14 
     Other malignancies 7 8 
     Non-malignant 10 3 
     Disease stage, early/late 53/50 36/61 
Conditioning regimen, number of patients:   
     MAC/RIC 28/75 28/69  
     TBI-based 31  39 
     ATG 78  69 
Donor, number of patients:   
     Sibling/MUD 28/75 31/66 
     Median donor age, years (range) 28 (4‒66) 32 (7‒66) 
     Female to male, number of patients 14 14 
HSCT graft, number   
     BM/PBSCs 21/82 18/79  
     TNC dose, ×108/kg (range) 9.3 (1.8‒34.0) 11.1 (1.8‒42.8) 
     CD34+ cell dose, ×106/kg (range) 6.6 (1.2‒22.8) 6.3 (1.3‒19.7) 
Table 4. patient characteristics in paper I 
In paper II-IV, donor stem cell grafts were collected and used to characterize γδ T cell 
composition. A total of 105 donor grafts were analyzed in paper II (Table 5) and the results 
were correlated to clinical outcome in corresponding recipients. In Paper III, the phenotypic 
and clonotypic characteristics of CD8+γδ T cells were explored in 16 BMSC graft samples 
from CMV+ (n=7) and CMV- (n=9) donors. In paper IV, CDR3 repertoire of TCR γ chain 
was analyzed by NGS. In total, 20 PBSC grafts that were transplanted to AML patients were 
assessed (Table 6). 
In paper V, MNCs from UCB (n=8) and healthy donors PB (n=3) were used for in vitro 
expansion and subsequent functional and phenotypic characterization of γδ T cells. UCB 
units were collected from healthy volunteers giving birth at the maternity ward at Karolinska 
University Hospital in Huddinge and were unlabeled to prevent tracking of the donor 
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Characteristics Recipients Donors 
   
Total Number 105 105 
Gender: Female/Male, n 43/62 40/65 
Age, median (IQR), yr. 52 (31.5-61) 30 (23-38.5) 
CMV serostatus pre- HCT, - /+, n 21/84 45/58 
Donor type, sibling/MUD/others, n  28/66/11 
Underlying disease, n   
Acute leukemia 54  
Chronic leukemia 7  
Myelodysplastic syndrome 19  
Others  25  
Disease status: High risk/low risk, n 57/48  
Conditioning regimen, MAC/RIC n 26/79  
Graft source, BM/PB n  16/89 
Relapse, n 25  
CMV reactivation, n 40  
ATG: Yes/No, n 70/35  
GvHD prophylaxis, n   
Cyclosporin A + Methothrexate 92  
   
Table 5. Patient characteristics in paper II 
 
Variable Recipients  Donors 
Total number 20 20 
Median age, years (range) 59.5 (38.5-64.5) 30 (23-35.7) 
Sex, number of males/females 7/13 11/9 
Diagnosis, number of patients AML (20)  
Conditioning regimen, MAC/RIC 5/15  
Donor type, Sibling/MUD:  3/17 
HSCT graft source, number   PB (20) 
CMV serostatus (+/-) 15/5 7/13 
CMV infection (yes/no) 12/8  
GVHD prophylaxis CSA+MTX  
aGVHD, (0-I/II-III) 13/7  
cGVHD, no or mild/moderate and severe 17/3  
Relapse, Yes/no 8/12  
Table 6. Patient characteristics in paper IV 
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3.2 LABORATORY METHODS 
Laboratory techniques used in this thesis varied among constituent papers (Figure 11). The 
main methods used included immunophenotyping, functional assays and molecular PCR-
based techniques. The main workflow can be summarized in the following chart. 
 
Figure 11. A flowchart showing the workflow and laboratory methods used in the thesis 
3.2.1 MNCs isolation and cryopreservation 
Samples were collected in vacutainers containing appropriate anticoagulant (Heparin). 
Mononuclear cells (MNCs) were freshly isolated by density gradient centrifugation using 
Lymphoprep (Fresenius Kabi, Oslo, Norway). The centrifugation step was set at 800g for 20 
minutes with no brake.  The buffy coat layer containing the MNCs was collected and washed 
twice with phosphate buffered saline (PBS) prior to cell counting. MNCs were either freshly 
used in subsequent laboratory methods or cryopreserved (in most cases) at –196°C. Freezing 
media consisted of 10% DMSO in RPMI-1640 medium (HyClone, Thermo Fisher Scientific 
Inc., Waltham, MA), containing 10% human AB-serum (Karolinska University Hospital, 
Huddinge, Sweden) and supplemented with 2 mM L-glutamine (Gibco, Life Technologies, 
Paisley, UK), 100 IU/mL penicillin G, and 100 mg/mL streptomycin (Gibco). 
3.2.2 Immunophenotyping by Flow cytometry 
3.2.2.1 Basic principles  
Flow cytometry is a powerful high throughput instrument that allows characterization of cells 
at a single cell level. Flow cytometry consists of two main components: a fluidic system and 
a detection system (Figure 12) (161). 
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The role of the fluidic system is to create a laminar flow with hydrodynamic focusing. This 
hydrodynamic focusing forces the cells in the flow cell chamber to flow in single cell layer, 
allowing the passage of one single cell through the nozzle at a time. 
The detection system is composed of light sources (lasers) that emit lights at different wave 
lengths, optical filters, and photomultiplier tube (PMT) detectors. As the cells pass through 
the light beam, light is scattered in different directions and can be collected by different 
channels. The light detected by the forward scatter channel (FSC) reflects the size of the cell, 
whereas that detected by side scatter channel (SSC) provides information about cell 
complexity. 
Besides FSC and SSC, more specific markers can be detected by staining cells with 
fluorochrome-conjugated antibodies. These fluorochromes, once excited by light beam, emit 
light at specific wavelength that can be collected through appropriate filters and detectors. 
 
Figure 12. Basic components of flow cytometry 
3.2.2.2 Cell surface staining 
Cell surface staining was performed as a standard technique in all papers. Briefly, MNCs 
were washed with PBS and resuspended in PBS in a concentration of 1-2 ×106 cells/mL. 200 
µl of cell suspension was used for surface staining in plates. Plates were centrifuged and the 
cell pellets were resuspended in 100 µl of PBS containing specific fluorochrome-conjugated 
monoclonal antibodies (mAbs). The amount of used mAbs was estimated after initial 
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titration. Cells were mixed and incubated in fridge (dark) for 30 minutes. After incubation 
cells were centrifuged and washed twice with PBS and resuspended in 50 µl PBS. Cell 
viability stain was then added (2 µl of 7-AAD) and plates were incubated for 7 minutes in the 
dark at room temperature. At the end 200-250 µl of PBS was added and cells were transferred 
to FACS tubes for analysis. 
Samples were acquired by FACS Canto (BD) and results were analyzed by FlowJo software 
(BD). For each run, appropriate controls were included. Single color stained beads 
(compensation beads, BD) were used to create the compensation matrix, and fluorochrome 
minus one (FMO) controls were used for proper gating of cell populations. A list of mAbs 
used for surface staining are shown in Table 7 
Marker Fluorochrome Clone Vendor 
7-AAD - - BD Biosciences 
ANNEXIN V FITC  BD Biosciences 
CD3 PE UCHT1 BD Biosciences 
CD3 V450 UCHT1 BD Biosciences 
CD3 BV510 UCHT1 BD Biosciences 
CD4  Alexa Fluor 700 RPA-T4 BD Biosciences 
CD8  APC-Cy7 SK1 BD Biosciences 
CD8 FITC SK1 BD Biosciences 
CD8 V500 RPA-T8 BD Biosciences 
CD19 PE HIB19 BD Biosciences 
CD25 FITC M-A251 BD Biosciences 
CD27  BV421 M-T271 BD Biosciences 
CD27 PE M-T271 BD Biosciences 
CD28 FITC CD28.2 BD Biosciences 
CD45RO APC UCHL1 BD Biosciences 
CD56 BV421 NCAM16.2 BD Biosciences 
CD69 FITC FN50 BD Biosciences 
CD94 FITC HP-3D9 BD Biosciences 
CD95 FITC DX2 BD Biosciences 
CD197 (CCR-7)  PE-Cy7 3D12 BD Biosciences 
CD314 (NKG2D) BV421 1D11 BD Biosciences 
CD107a BV510 H4A3 BD Biosciences 
TCRαβ FITC T10B9.1A-31 BD Biosciences 
IFN-γ PE-Cy7 B27 BD Biosciences 
TNF-α PE-eFluor 610 MAb11 eBioscience 
TCR Vδ2 FITC B6 Biolegend 
TCR Vγ9 FITC B3 Biolegend 
CD158 PE-Cy7 DX27 Biolegend 
CD152 (CTLA4) FITC A3.4H2.H12 Lifespan Biosciences 
CD223 (LAG-3) FITC 17B4 Lifespan Biosciences 
CD366 (TIM-3) APC F38-2E2 Lifespan Biosciences 
CD159a (NKG2A) APC REA110 Miltenyi Biotec 
TCR pan γδ  PE REA591 Miltenyi Biotec 
CCR-9 APC Clone # 248621 R&D SYSTEMS 
TCR Vδ1 FITC TS8.2 Thermo Scientific 
TCR γδ FITC IMMU510 BECKMAN COULTER 
    
Table 7. a list of fluorochrome conjugated mAbs used in the thesis 
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3.2.2.3 Intracellular staining (ICS) 
ICS was performed in paper II to evaluate cytokine and degranulation of γδ T cells in 
response to mixed lymphocyte reaction (MLR). In such long incubation experiments, 
brefeldin A (BFA) was added to the media in the last 8 hours of incubation, while CD107a 
was added at the beginning. After staining for surface markers, cells were fixed and 
permeabilized using cytofix/cytoperm kit (BD) and were incubated for 15 min in the fridge. 
Next, cells were washed twice and resuspended in 100 µl of staining buffer solution 
(Cytofix/cytoperm kit) containing conjugated mAbs for the specific cytokines. After 30 min 
of incubation in the fridge, cells were washed twice and resuspended in PBS and acquired by 
FACS.   
3.2.3 Mixed lymphocyte reaction (MLR) 
MLR was used to study alloreactive responses elicited by T cells (responders) when 
cocultured with allogeneic irradiated MNCs (stimulators). The irradiation step was crucial to 
prevent proliferation of stimulators. In paper II, I used a modified MLR protocol to 
investigate the alloreactivity of γδ T cells. Briefly, MNCs from stem cell grafts or in vitro 
cultured γδ T cells were used as responders. The MLR coculture consisted of allogeneic 
responder cells that were labeled with 2 μM of CellTrace™ Violet Cell Proliferation Kit 
(ThermoFisher), and irradiated MNCs (stimulators). A condition without stimulators was 
used as control. The responder/stimulator ratio was 5:1, and the coculture was incubated for 5 
days (37 °C and 5% CO2). Samples were analyzed by flow cytometry for proliferation and 
activation markers. 
3.2.4 Cell purification and sorting 
Cell purification and sorting was performed in all papers. For isolation of untouched T cells 
pan T cell isolation kit was used. γδ T cell purification was performed using a positive 
selection kit (human TCR γ/δ+ T Cell Isolation Kit, Miltenyi Biotec), or negative selection 
kit. For magnetic beads sorting, a selection buffer consisting of PBS containing 0.5% human 
serum albumin and 2 mM EDTA was used. In paper III, higher purity of CD8+/CD8− γδ 
fractions could be achieved by FACS sorting (Sony MA900, Sony Biotechnology Inc.). 
3.2.5 Ex vivo expansion of Vγ9Vδ2 T cells 
In vitro expansion of Vγ9Vδ2 T cells from UCB samples was a substantial experiment in 
paper V. Initially, cryopreserved MNCs from UCB samples were thawed, washed with PBS, 
and counted. CD56+ cells (NK cells) were depleted prior to culture using CD56-APC 
conjugated mAbs (BD Bioscience, Franklin Lakes, NJ, USA) and anti-APC microbeads 
(Miltenyi, Bergisch Gladbach, Germany) according to manufacturers’ instructions. CD56 
depleted MNCs were counted and then resuspended in RPMI-1640 media (Gibco) containing 
10% human AB-serum (Department of Transfusion Medicine at Karolinska University 
Hospital Huddinge), supplemented with 2mM L-glutamine, 100 IU/ml penicillin G, 100 
mg/ml streptomycin, and 0.25 mg/ml amphotericin B. Cells were seeded in appropriate cell 
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culture flasks in a final concentration of 1 × 106 viable mononuclear cells/ml. At day 0, 
human recombinant IL-2 and the bisphosphonate zoledronate were added in varying 
concentrations (0–500 IU/ml and 0–10 μM, respectively). Cultured cells were then incubated 
at 37°C at 5% CO2. Every other day, viable cells were counted using trypan blue exclusion 
and IL-2 containing media was added to maintain cell concentration. On day 7, cultured cells 
were counted, and the media was replaced completely. On day 14, cells were harvested, 
counted, and cryopreserved as mentioned earlier. 
3.2.6 T Cell proliferation assay 
T cell proliferation assays were performed as part of MLR or after cytokine or TCR 
stimulation to assess γδ T cell responses. Briefly, MNCs or purified CD3+ T cells were 
washed in PBS and centrifuged at 300g for 10 minutes. The cell pellet was then resuspended 
in 1 mL of PBS containing CellTrace violet (Thermofisher) diluted to final concentration of 
2.5 µM and incubated in dark for 10 minutes at 37°C. Next, labeled cells were diluted 5 times 
with complete media, kept for another 5 minutes, and then washed with PBS before use in 
subsequent experiments. Labeled T cells were cultured in a 96-well plate (1 × 106 cells/mL) 
in a complete RPMI-1640 medium, either stimulated or unstimulated, and were incubated at 
37°C and 5% CO2 for 5 or 7 days. Cells were analyzed by FACS, and proliferating cells 
were defined as % of Cell-Trace violet (CTV) low cells compared to unstimulated conditions 
(Figure 13).  
 
Figure 13. Assessment of cell proliferation using cell trace violet 
3.2.7 Cytotoxicity assays 
The ability of γδ T cells to kill cholangiocarcinoma cancer cell line (Hucct-1) was assessed in 
paper V using a cytometry-based assay (162). Briefly, Hucct-1 cells were labeled with the 
CellTrace™ Violet Cell Proliferation marker (Thermo Fisher). Next, expanded UCB and PB 
γδ T cells were cocultured with target tumor cells at an effector: target ratio of 10:1 and 
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incubated at 37°C, with 5% CO2 for 24 hours. Cell viability was then assessed by flow 
cytometry in CTV positive cells using annexin V. The % of target cell killing was calculated 
with the formula 
% 𝐶𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 = 100 −
% 𝑣𝑖𝑎𝑏𝑙𝑒 𝐶𝑇𝑉 + 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑐𝑜𝑐𝑢𝑙𝑡𝑢𝑟𝑒
% 𝑣𝑖𝑎𝑏𝑙𝑒 𝐶𝑇𝑉 + 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 𝑋100 
3.2.8 Polymerase chain reaction (PCR)-based methods 
3.2.8.1 Basic principles 
PCR is a powerful tool that enables amplification and subsequent detection and quantification 
of DNA and RNA targets (Figure 14). The PCR reaction mix ideally consists of DNA/cDNA 
template, and a master mix that contains the polymerase enzyme, necessary nucleotides, 
forward (Fwd) and reverse (Rev) specific primers in final optimized concentrations. 
Occasionally a fluorescent labeled probe is used. The PCR reaction volume is usually 50, 25, 
or 10 µl. 
 
Figure 14. Illustration of main steps of PCR 
The amplification of DNA occurs in cycles (35-40). Each PCR cycle consists of several steps 
that vary in duration and temperature according to the specific application. In general, three 
main steps are involved: 1-Denaturation step: usually at 95 ºC for 15-30 sec. The aim of 
denaturation is to separate the double stranded DNA into single strands. 2-Annealing step: 
during this step, the forward and reverse primers specifically bind (anneal) to their 
complementary nucleotide sequences in the DNA template. The annealing temperature 
depends on the melting temperature of each primers. Common commercially available 
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primers are usually optimized to anneal at 60 ºC for 1 min. 3-Elongation (extension) step: 
usually at 72 ºC for 1 min. In some cases, the annealing and extension steps are combined in 
one step.   
3.2.8.2 Cytokine gene expression 
Cytokine genes were quantified using a two-step reverse transcriptase PCR (RT-PCR) 
method (163). In the first step, RNA was extracted from sorted γδ T cells (TCR γ/δ T cell 
isolation kit, Miltenyi) using the PureLink™ RNA Mini Kit (Invitrogen, ThermoFisher) and 
converted to cDNA using Super- Script™ IV VILO™ Master Mix (ThermoFisher) according 
to manufacturer’s instructions. The cDNA can be used immediately or kept at -20°C.  
In the second step, cDNA products resulting from the 1st step were used as template for 
amplification of specific gene segments using predesigned TaqMan Gene Expression Assays 
for IL-1B, IL-2, IL-6, IL-7, IL-8, IL-12B, IL-15, and IL-17 genes and human ACTB gene as 
reference gene (Thermofisher scientific). PCR was performed using a 7500 fast real-time 
PCR instrument (Applied Biosystems). 
3.2.8.3 TREC and KREC assessment 
Somatic recombination occurs in all TCR genes. This TCR rearrangement process results in 
production of circular DNA products known as T cell receptor recombination excision circle 
(TREC). However, not all TRECs are appropriate for laboratory assessment. 
 
Figure 15. Illustration of signal joint TREC and coding joint TREC 
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A good candidate TREC must be detectable in peripheral blood and not affected by the 
different rearrangement possibilities. As rearrangements of TRB and TRG loci are very early 
events, their resulting TRECs are extensively diluted before they enter the peripheral blood 
rendering their levels in the PB below the detection limit (88). 
Alternatively, somatic recombination of TRA locus demands the deletion of the TRD gene 
locus as it is interspersed with TRA along the same chromosomal location. Since this deletion 
occurs at a relatively late developmental stage, the generated TRECs are less subjected to the 
dilution effect of thymocyte expansion. Furthermore, this rearrangement results in production 
of δRec-ΨJα signal joint and coding joint in 70 % of cases (Figure 15) (164). 
Likewise, B cells undergo somatic recombination of their immunoglobulin heavy and light 
chains. The rearrangement process of the kappa gene results in kappa deleting recombination 
excision circle (KREC) that can be used as surrogate for newly produced naïve B cells (165). 
In the first paper, we used a TaqMan real-time PCR based technique  to quantify TREC and 
KREC levels from genomic DNA extracted from CD3+ and CD19+ sorted samples, 
respectively (Figure 16) (165). Briefly, a multiplex PCR reaction was developed for 
TREC/GAPDH in a final volume of 25 µl, consisting of 12.5 µl of TaqMan™ 2X Universal 
PCR Master Mix (Applied Biosystems), sjTREC primers (forward 5'- CAC ATC CCT TTC 
AAC CAT GCT; reverse 5'-GCC AGC TGC AGG GTT TAGG) and probe (6-FAM-ACA 
CCT CTG GTT TTT GTA AAG GTG CCC ACT) were added in a final concentration of 300 
and 200 nM respectively, and GAPDH primers (forward 5'-GGA CTG AGG CTC CCA CCT 
TT; reverse 5'-GCA TGG ACT GTG GTC TGC AA) and probe (VIC-CAT CCA AGA CTG 
GCT CCT CCC TGC) were added in a final concentration of 150 nM and 100 nM 
respectively. For KREC quantification, we used KREC primers and probes that were 
described by Sottini et al., (165)in a final concentration of 900 nM and 200 nM respectively 
and GAPDH as for TREC. PCR amplification was performed on a 7500 Fast Real-Time PCR 
System (Applied Biosystems, Foster City, CA, USA). The PCR cycling conditions were as 
follows: 1× (95°C for 10 min), 40× (95°C for 15 sec, 60°C for 1 min). TREC and KREC 
values were calculated relative to GAPDH using the formula 2(∆Ct), where ∆Ct = Ct GAPDH-
Ct TREC (KREC) 
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Figure 16. Illustration of the TaqMan PCR method used for TREC and KREC quantification 
3.2.8.4 Telomer length (TL) assessment 
TL was assessed by quantification of telomere DNA relative to the DNA of a single copy 
gene (T/S) as described before (166). Briefly, for each sample, telomere and human Beta 
globulin (HBG) gene DNA were amplified separately as triplicate in a MicroAmp Fast 
Optical 96 well plates, using SYBR green PCR technique. 
A reaction mix was prepared separately for telomere and HBG with a total reaction volume 
of 20 µl containing Power SYBR green PCR Master Mix (Applied Biosystems) in a final 
concentration of 1×. For telomere DNA, forward and reverse primers in a final concentration 
of 100 and 900 nM, respectively, were added. Whereas for HBG DNA, forward and reverse 
primers in final concentration of 300 and 700 nM, respectively, were added. DNA samples 
were finally added to each well in a final amount of 25 ng. The PCR was performed on a 
7500 fast real-time PCR-system (Applied Biosystems) using the following PCR conditions: 
1× (10 min 95°C), 40× (15 sec 95°C, 1 min 60°C). Mean Ct values were determined for both 
telomere and HBG. And T/S ratio was calculated as follow: T/S = 2∆Ct where ∆Ct = (mean Ct 
HBG – mean Ct telomere). The following primers were used: Tel1b-Forward: CGG TTT 
GTT TGG GTT TGG GTT TGG GTTTGG GTT TGG GTT; Tel2b-Reverse: GGC TTG 
CCT TAC CCT TAC CCT TAC CCT TAC CCT TAC CCT; Hbg1-Forward: GCT TCT 
GAC ACA ACT GTG TTC ACT AGC; Hbg2-Reverse: CAC CAA CTT CAT CCA CGT 
TCA CC 
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Importantly, SYBR green based method can result in non-specific amplifications. Therefore, 
results should be carefully analyzed to avoid false results. In order to minimize this 
limitation, the following measures were implemented: 1- Appropriate controls were used; 
non template control and positive control sample obtained from acute myeloid leukemia cell 
line (THP-1). 2-Melting curve analysis was performed after amplification (Figure 17) to 
discriminate non-specific amplifications. 3-All samples were run as triplicates. Furthermore, 
samples from different time points for the same recipient were included in the same run 
simultaneously, to minimize plate to plate variations 
   
Figure 17. Melting curve performed following SYBR green PCR for TL. To the right a melting curve generated from 
specific amplification. To the left a melting curve from non-specific amplification  
3.2.9 TCR repertoire analysis 
3.2.9.1 CDR3 size spectratyping 
This technique was used in paper II and V to explore the CDR3 repertoire of γδ T cells 
(Figure 18). Genomic DNA was used in multiplexed PCR reactions using primers listed in 
Table 8 to amplify 12 δ and 9 γ chain rearrangements. Briefly, the PCR was performed using 
AmpliTaq Gold 360 Master Mix (Applied Biosystems), specific primers in a final 
concentration of 200 or 400 nM as indicated (Table 8 and 9) and 100 ng of DNA, with a 
thermal cycler PCR machine (PTC-200, MJ Research, Watertown, MA). The process 
included the following steps: initial denaturation at 95°C for 10 minutes, followed by 35 
cycles each of 94°C for 30 sec, 60°C for 45 sec, 72°C for 60 sec, and a final elongation step 
at 72°C for 10 minutes. 
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Primer  Sequence 
Vδ1 (FAM)-ATGCAAAAAGTGGTCGCTATT 
Vδ2 (NED)-ATACCGAGAAAAGGACATCTATG 
Vδ3 (VIC)-GTACCGGATAAGGCCAGATTA  
Jδ1 GTTCCACAGTCACACGGGTTC 
Jδ2 GTTCCACGATGAGTTGTGTTC 
Jδ3 CTCACGGGGCTCCACGAAGAG 
Jδ4 TTGTACCTCCAGATAGGTTCC 
VγfI GGAAGGCCCCACAGCRTCTT     
Vγ10 AGCATGGGTAAGACAAGCAA 
Vγ9 CGGCACTGTCAGAAAGGAATC 
Vγ11 CTTCCACTTCCACTTTGAAA 
Jγ1.1/2.1 (FAM)-TTACCAGGCGAAGTTACTATGAGC 
Jγ1.3/2.3 (NED)-GTGTTGTTCCACTGCCAAAGAG 
Jγ1.2 (FAM)-AAGAAAACTTACCTGTAATGATAAGC 
Table 8. primer sequences used in γδ TCR spectratyping  
 
A) TCR-δ tubes V primer/s J primer/s Final primer conc. 
1 Vδ1 (FAM) Jδ1 200 nM each 
Vδ2 (NED) 
Vδ3 (VIC) 
2 Vδ1 (FAM) Jδ2 200 nM each 
Vδ2 (NED) 
Vδ3 (VIC) 
3 Vδ1 (FAM) Jδ3 200 nM each 
Vδ2 (NED) 
Vδ3 (VIC) 
4 Vδ1 (FAM) Jδ4 400 nM each 
Vδ2 (NED) 
Vδ3 (VIC) 
B) TCR-γ tubes    
5 Vγ10  
Vγfl 
Jγ1.3/2.3 (NED) 
Jγ1.1/2.1 (FAM) 
200 nM each 
6 Vγ11  Jγ1.3/2.3 (NED) 
Jγ1.1/2.1 (FAM) 
400 nM each 
7 Vγ9 Jγ1.3/2.3 (NED) 
Jγ1.1/2.1 (FAM) 
200 nM each 
8 Vγ9  Jγ1.2(FAM) 400 nM each 
    
Table 9. primers used for multiplex PCR  
Next, the products of PCR amplification were analyzed to determine their CDR3 length using 
capillary electrophoresis where each PCR product was mixed with formamid (FA, HiDi 
Formamide) and a size standard (GeneScan 400HD Rox Size std, Applied Biosystems) in 96-
well MicroAmp plates (Applied Biosystems). Samples were analyzed using 3130 × 1 Genetic 
Analyzer (Applied Biosystems). The results were analyzed using the PeakScanner software 
(Applied Biosystems). 
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Figure 18. Illustration of the steps of TCR spectratyping 
3.2.9.2 Next generation sequencing (NGS) 
Basic principles 
The advent of NGS has fundamentally revolutionized the field of genomics by providing 
sequencing solutions that were previously non feasible. NGS technology is rapidly evolving, 
and different platforms are currently available in the market. However, they use the same 
basic principle. 
NGS and capillary electrophoresis share similar basic concept. NGS however is much rapid 
and accurate, as it is capable of sequencing millions of fragments in a massively parallel 
fashion thus reducing the cost of sequencing. In principle, the NGS workflow consists of 
three basic steps: library preparation, sequencing, and data analysis (Figure 19) (167). 
Library preparation: during this step, DNA or RNA are fragmented and ligated to specialized 
adapters. These fragments can then be amplified and purified. During the sequencing step, 
libraries are loaded onto a flow cell and placed on the sequencer. The clusters of DNA 
fragments are amplified, resulting in millions of copies of single-stranded DNA. After 
sequencing, generated data are analyzed using specialized analysis pipeline.  
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Figure 19. Basic steps of next generation sequencing 
In paper III and paper IV, genomic DNA was extracted from purified γδ T cells using the 
EZ1 DNA Blood Kit and EZ1 instruments (QIAGEN, Hilden, Germany) and stored at -20°C. 
The extracted DNA was used for survey-level deep sequencing of the γ-chain using the 
ImmunoSEQ platform by Adaptive Biotechnologies (Seattle, WA). Briefly, V-J segment 
rearrangements were amplified in a bias-controlled reaction (168) and sequencing errors were 
corrected using a clustering algorithm. CDR3 segments were annotated according to the 
International ImMunoGeneTics collaboration and V and J genes for each rearrangement was 
identified (169).  
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Sequencing data were initially analyzed using the ImmunoSEQ Analyzer (adaptivebiotech), 
followed by post-analysis of TRG repertoire diversity, clonal space homeostasis, segment 
usage, spectratyping, and repertoire overlap using the tcR package (170), VDJTools (171), 
and VDJviz browser (172). NGS data are available at the Adaptive Biotechnology 
ImmunoSEQ site (https://clients.adaptivebiotech.com) 
3.3 STATISTICS METHODS 
Non-parametric (two-tailed) tests were used throughout the thesis unless specified otherwise. 
When parametric tests were used the assumptions of normality were confirmed using the 
Shapiro test and Q-Q plots. 
Chi-square test was used to compare categorical variables, while continuous variables were 
compared using the Mann-Whitney U test. Correlations between given variables were 
investigated using the nonparametric test of Spearman's rank correlation coefficient.  
Analysis of variance (NOVA) followed by post hoc multiple comparisons with Tukey’s 
correction were used when three or more unrelated groups were compared, and repeated 
measures ANOVA was used for related (paired) groups 
γδ Cell subsets were presented as % of total T cells throughout the thesis unless otherwise 
stated. Survival function was estimated using the Kaplan-Meier method and group 
differences were compared using the log-rank test. The incidence of TRM was investigated 
using an estimator of cumulative incidence curves. Patients were censored at the time of 
death or last follow-up. For multivariate analysis, logistic regression was used to evaluate 
factors affecting TREC, KREC, and telomeres. 
2-sided P value <.05 was considered statistically significant for all tests. Statistical analyses 
were performed using Statistica software (StatSoft, Tulsa, OK), EZR software, GraphPad 
Prism version 6.00 for Windows (Graph-Pad Software, La Jolla, California, USA) and SPSS 
Statistics (IBM, Armonk, NY, USA). 
3.4 ETHICAL CONSIDERATIONS 
All the research work is conducted in compliance with the declaration of Helsinki, applicable 
regulations and directions, and is covered by ethical approvals from the Regional ethical 
committee in Stockholm. All study subjects are covered by the Swedish Patient Insurance 
(LFF) and the Swedish Pharmaceutical Insurance. It is of upmost importance to be honest, 
not give false hope and strictly follow ethical and safety guidelines in order to not invoke 
harm or false expectations. This is also important with regards to research that deals with 
collection of samples. It is important to be clear that potential results might not directly 
benefit the study participant but instead future patients. 
Additional ethical aspects within the preclinical part of the research include collection of 
blood samples from healthy individuals/donors and patients. Blood collection of maximum 
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50 ml/sample is considered safe for the donor and was done at Karolinska University 
Hospital by qualified personal.  
Regarding data management, all data on patients are stored in a quality register located under 
the supervision of Karolinska University Hospital. The register is continuously updated and 
controlled. All patients will be informed and give their informed consent prior to being 
included in the register. Personal identification numbers and all information are kept strictly 
confidential and patients are coded upon publication or exposure to individuals outside the 
hospital or project. 
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4 RESULTS AND DISCUSSION 
4.1 EVALUATING TREC, KREC AND TL FOLLOWING ALLOGENEIC HSCT 
(PAPER I) 
Efficient recovery of the adaptive immune system following allogeneic HSCT is pivotal for 
beneficial outcome. The replenishment of the virtual empty lymphocyte pool occurs through 
cytokine driven homeostatic expansion of donor mature lymphocytes and through de novo 
generation of naive lymphocytes from HSCs precursors. The latter can be monitored by 
assessing TREC and KREC levels in the PB (164). These excision circles have been 
suggested as reliable molecular surrogate markers for recent thymic T cell emigrants and B 
cell neogenesis, respectively (173). 
Additionally, lymphocytes undergo massive proliferation, particularly during the early 
periods post HSCT. To maintain efficient proliferative capacity, cells require telomere, a 
short tandem repeat of nucleotide sequences (5´-TTAGGG-3´) found at chromosomal ends. 
These telomeres undergo continuous shortening with each cell division. Extensive telomere 
shortening of rapidly proliferating lymphocytes can predispose to immune senescence with 
resulting impaired immune response or secondary malignancies (174). 
We and others have previously assessed TREC, KREC, and TL, to address lymphocyte 
neogenesis kinetics in relation to different transplant related factors (164, 175). Nevertheless, 
little is known about the impact of GVHD prophylaxis regimens on newly generated 
lymphocytes. In this prospective randomized study (paper I), we sought to address whether 
these markers are influenced by using different GVHD prophylaxis regimens. More 
specifically, we compared between CsA/Mtx vs Tac/Sir as two GVHD prophylaxis arms. 
Our findings indicated no significant differences in TREC, KREC or TL between the two 
prophylaxis regimens at any assessed time point. Consistently, there was no differences in the 
absolute counts of the main lymphocyte subsets between the two patient groups. Indeed, in 
the clinical part of this study, that was published earlier, the incidence and severity of 
aGVHD was comparable between the two treatment arms, supporting the findings in this 
paper, as it would have been conceivable to detect differences in these markers if one 
prophylaxis regimen was associated with increased incidence or severity of GVHD (176). 
Tacrolimus and Sirolimus exert their suppressive effects through distinct pathways, by either 
inhibition of Calcineurin or mTOR respectively. Sirolimus is commonly used to prevent graft 
rejection in solid organ transplantation (177). In HSCT, the use of Sirolimus was associated 
with vascular endothelial injury (178). Importantly, in this study Sirolimus was given for 
relatively shorter duration (<6 months). Thus, the long-term effect of Sirolimus cannot be 
excluded. Furthermore, Sirolimus was given in combination with Tac (a calcineurin 
inhibitor), therefore, the sole effect of Sirolimus has not been tested in this study. 
In line with previous research, we showed that TREC and KREC levels ascend gradually 
while TL shortening occurs during follow up. While KREC levels increased significantly by 
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6 months, TREC levels were significantly increased after 12 months. This indicates that 
KREC recovers earlier than TREC post allogeneic HSCT. The observed kinetics of TREC 
recovery fits alongside with the reported thymic rebound and highlights that T cell recovery 
is much slower process. In this regard multiple studies showed that TREC levels recover 
slowly and their levels remain low several years after HSCT, suggesting that thymic recovery 
post HSCT is a slow process or probably never achieved (179). 
Consistent with previous studies, we showed a significant association between lower TREC 
levels and older age, the use of ATG and PB as graft source (Figure 20) (180). Age 
associated thymic involution is a well know phenomenon (181). The effect of recipient age 
was prominent in our study as it appeared as independent significant factor in multivariate 
analysis. This effect should therefore be considered when other factors are interpreted. 
  
  
Figure 20. Impacts of patient age (A), ATG treatment (B),  graft source (C) on TREC levels after HSCT; Impact of 
aGVHD (D) on KREC levels after HSCT. 
Graft source has been shown to influence the immune reconstitution pattern (75). The 
comparison between different graft sources is however precluded by the existence of 
confounders. In this study, BM as graft source was associated with higher TREC levels at 12 
and 24 months. This might suggest that BM grafts preferentially contain supporting cells such 
as mesenchymal stromal cells, that play potential role in thymic regeneration. On the other 
hand, elevated TREC levels in BM graft recipients could reflect confounding factors. 
cGVHD is more commonly seen in PB recipients (28) and in the present study, TREC levels 
were lower in patients with severe cGVHD. Additionally, most BM graft recipients in this 
study were younger age compared to PB recipients.  
D 
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In vivo depletion of T cells by ATG is commonly used during conditioning to prevent GVHD 
and reduce risk of graft rejection (74). Here, we showed that the use of ATG was associated 
with lower TREC levels. Though ATG has a short half-life (days), the decrease in TREC 
levels was detected up to 6 months post HSCT. This is of clinical significance since 
insufficient T cell recovery predisposes to increased risks of opportunistic infections. Patients 
receiving ATG should therefore be carefully monitored for early signs of infection. 
Unlike TREC, aGVHD was the only factor that negatively impacted KREC recovery. 
Patients with aGVHD grade II-IV had lower KREC levels at 2, 3, and 6 months. Interestingly 
this difference disappeared by 12 months suggesting that aGVHD has a transient impact on 
BM. 
Our results extend previous work showing that early recovery of TREC and KREC is 
associated with beneficial outcome. Patients with low TREC levels have higher risk of death 
due to infection complications. Further studies are required to show the benefit of 
antimicrobial prophylaxis in those patients. 
4.2 EVALUATING THE IMPACT OF GRAFT γδ T CELLS ON ALLOGENEIC 
HSCT OUTCOME (PAPERS II-IV) 
The vast majority of γδ T cells exert potent anti-tumorous, anti-viral immune response 
independent of MHC recognition. This unique feature of γδ T cells is particularly significant 
in the field of allogeneic HSCT as it renders γδ T cells able, in theory, to eliminate leukemic 
blasts without initiating unwanted GVHD.  
Multiple studies have investigated the impact of γδ T cells on patient outcome post HSCT. 
Early reconstitution of γδ T cells was correlated with less incidence of relapse and increased 
OS. Furthermore, patients with higher γδ T cells have shown less incidence of TRM and 
severe infection (132, 133, 135). Nevertheless, the role of γδ T cells in GVHD has remained 
open question. Few studies have suggested a pathogenic role of γδ T cells and potential 
association with GVHD (144), while large body of evidence indicated that γδ T cells are not 
key effectors in GVHD initiation. 
This contrariety between studies can be attributed to the variation among different studies. 
Most of the clinical studies have investigated this complex association indirectly by 
demonstrating the outcome in patients that received manipulated grafts depleted of αβ cells 
(182, 183), or by monitoring γδ T cell reconstitution post HSCT (126). Importantly, the 
mechanistic analysis has been conducted in mice models. Given the limitations of using 
mouse models in the dissection of complex GVHD biology, results from mice studies should 
be carefully interpreted. 
Additionally, few studies have investigated the impact of graft γδ T cells. importantly, most 
of the available studies have assessed total γδ T cells while the impact of different subsets has 
not been thoroughly investigated. Given the diversity in function and biology of γδ subsets, 
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we sought, in papers II-IV, to in-depth characterize intra-graft γδ cells to better alleviate their 
role in allogeneic HSCT outcome. 
In paper II we identified a subset of γδ T cells (CD8+ γδ cells) with a potential alloreactive 
impact. The graft proportion of this subset was significantly associated with increased 
incidence of aGVHD grade II-III (Figure 21).  
To account for the impact of ATG in 
the study we stratified patients in 
dichotomous groups (ATG and no 
ATG) and analysed the impact of 
CD8+ γδ cells. Results were 
consistent with the main analysis. 
Furthermore, we demonstrated 
experimentally that CD8+ γδ cells 
proliferation was enhanced and 
displayed activated phenotype when 
cultured in MLR (Figure 21). 
Moreover, CD8+ γδ cells showed 
increased frequencies of chemokine 
receptor 9 (CCR9) and CD69. Both 
are gut homing receptor/marker. 
Collectively, our findings from paper 
II suggest that CD8+ γδ cells in the 
stem cell graft could be an 
unidentified player in GVHD 
immunopathology. 
It is well established now that αβ T 
cells present in the donor graft are the 
key players inducing GvHD and their 
number directly correlates with an 
increased risk for GvHD (184, 185). 
To reduce incidence and severity of 
GVHD, several approaches for graft 
manipulation have been established 
using different methods of T cell 
depletion (185). The selective 
depletion of αβ T cells while 
retaining all other beneficial cells 
including γδ T cells in the graft has 
the advantage of maintaining antileukemic, antiviral and engraftment-supportive effects (69, 
92, 186). Contrastingly, Pabst et al. reported that patients who received PBSC grafts 
 
 
Figure 21.  Upper panel, the cumulative incidence of acute GvHD 
grade II–III for patients who received grafts containing higher 
(interrupted line) or lower (continuous line) T-cell proportions of 
CD8+γδ cells. Lower panel, a representative plot of cell proliferation 
after MLR, using in-vitro cultured γδ cells from PB of healthy 
subjects as responders. Blue histogram represents the MLR condition 
gated on CD8+γδ cells, green histogram represents MLR condition 
gated on CD8−γδ cells, and red histogram is the unstimulated 
condition (responders only). 
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containing higher doses of γδ T cells developed GVHD more frequently (145). While 
aGvHD was not correlated with the total graft γδ cell frequency in our study, we showed that 
a small fraction of γδ cells that co-express CD8 was associated with aGvHD grade II-III both 
in univariate and multivariable analysis. Therefore, the discrepancies between studies as to 
the impact of γδ cells may be justified by investigating the proportions of the various distinct 
subsets, such as CD8+γδ cells. 
While the vast majority of PB γδ T 
cells do not express CD4/CD8 co-
receptors and are MHC unrestricted, 
the immunobiology of CD8+ γδ T 
cells remains poorly understood. 
Whether the alloreactive response of 
these cells is MHC restricted or 
mediated by other undefined ligands 
is yet to be determined. In a recent 
study, Kierkels et al. described for 
the first time a novel allo-HLA–
restricted γδ T cell population. 
Interestingly the identified cells 
displayed CD8α coreceptor and 
expressed a TCR comprised of 
Vγ5Vδ1 (187). This novel subset 
was shown to recognize a peptide-
binding groove of HLA-A*24:02. 
Therefore, our finding in paper II 
could reflect analogous population. 
Given the poor understanding of 
CD8+γδ cells immunobiology, in 
paper III we sought to in-depth 
characterize this subset to gain more insights about their role. We identified donor CMV 
status as a significant factor associated with increased graft frequencies of CD8+ γδ cells. 
Further characterization showed that CD8+ γδ cells predominantly express Vγ9- chain. 
We next showed that the increased proportions of CD8+ γδ cells seen in the CMV+ donors 
were associated with differentiation from naïve (CD27 hi) to effector (CD27 lo) phenotype. 
Suggesting that CMV driven proliferation of CD8+ γδ cells follows an adaptive-like 
paradigm. NGS analysis of TRG repertoire highlighted that γδ cells from CMV+ donor graft 
proliferated in TCR dependent clonal fashion and showed abundant usage of Vγ9- segments. 
Furthermore, CD8+ γδ cells displayed enhanced response to TCR stimulation and respond 
differentially to various interleukins (Figure 22). Together, these findings support an 
adaptive-like yet unconventional phenotype of CD8+ γδ cells. 
 
 
Figure 22.  Upper panel, V-J segment pairing abundance in CDR3 
junctions of each donor based on CMV status. Chord diagrams are 
used for visualization. Ribbons connecting segment pairs are scaled by 
corresponding V-J pair frequency. Lower panel, representative 
histograms (n = 4) of proliferating T cells from unstimulated or 
TCR/CD3 stimulated condition, gated on TCR γδ- CD8+ (blue), 
CD8+γδ (green), and CD8-γδ (orange). 
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By combining results from paper II showing potential alloreactive role of intra graft CD8+ γδ 
cells and paper III showing that CD8+ γδ cells in grafts are CMV responsive, we could try to 
propose a possible scenario that links between CD8+ γδ cells in grafts and the occurrence of 
both CMV and GVHD post HSCT.   
As CD8+ γδ cells appeared to be CMV responsive, CMV reactivation in patients post HSCT 
would be expected to preferentially drive the expansion of CD8+ γδ cells particularly in 
patients that have received grafts from CMV+ donor already enriched with this subset. The 
expansion of CD8+ γδ cells would then mediate an alloreactive response and GVHD through 
yet undefined mechanisms. However, considering the complexity of the GVHD underlying 
immune mechanisms, it is more likely that CD8+ γδ cells are part of a multifaceted model 
that involves multidirectional cross talks between different immune subsets. Careful 
dissection of these mechanisms in experimental GVHD mice models can provide more 
insights. 
In paper II, we showed that higher graft content of CD27+ γδ cells were inversely correlated 
with relapse incidence and associated with less CMV reactivation in patients post HSCT. 
Unfortunately, we have not conducted functional assays to compare between CD27+ and 
CD27- γδ cells. Previous research have identified CD27 among other markers that are 
preferentially expressed by IFNγ producing γδ T cells, whereas IL-17 producing γδ T cells do 
not express CD27 (188). Given that IL-17 producing γδ T cells are associated with pro-
tumorous role, the presence of higher proportions of CD27+ γδ T cells (IFNγ producer) could 
in part explain the decreased incidence of relapse. However, this functional demarcation 
based on CD27 applies mostly to murine γδ cells. in humans, the functional division is less 
prominent. Another explanation could be that CD27 expression by γδ cells reflects a naïve-
like phenotype with better proliferative capacity and less exhausted phenotype, in addition to 
the more diverse TCR repertoire. 
In paper II, we used CDR3 size spectratyping method to address the impact of the TCR 
repertoire on clinical outcome. Though we could observe a potential association between 
graft γδ TCR repertoire and relapse, interpretation of these results was difficult as a result of 
sample heterogeneity beside the limitation of the spectratyping method. Based on the 
encouraging findings in paper II, we extended this work in paper IV by analyzing a 
homogenous group of 20 PBSC grafts given to AML patients. Analysis of TRG repertoire by 
NGS revealed important findings particularly in grafts given to non-relapsed patients. CDR3 
repertoire in grafts given to non-relapsed patients featured a more public repertoire and 
increased presence of long sequence clonotypes. Further analysis of the amino acid sequences 
from these CDR3 repertoires showed that 12 public and 4 private sequences were exclusively 
found in high frequencies in grafts given to non-relapsed patients. Most of these sequences 
were 42-54 amino acid long. Furthermore, we observed a bias in the V-J pairing in the form 
of decreased Vγ4-Jγ2/Vγ5-Jγ2/Vγ8-JγP2 and increased Vγ2-JγP1 pairing in grafts given to 
non-relapsed patients (Figure 23). 
 
  47 
 
 
 
Figure 23. (A) Quantification of homeostatic space taken up by the clones in relapsed and non-relapsed groups. (B) 
Frequency of unique CDR3 sequences with different nucleotide lengths. (C) Frequency of different TRGV-TRGJ 
rearrangements in the different groups. Bars represent median and interquartile range. *p < 0.05, two-tailed Mann–
Whitney U test 
The ability of γδ T cells to lyse leukemia cell lines has been confirmed experimentally. 
Furthermore, in different allogeneic HSCT settings, increased numbers of γδ T cells were 
associated with favorable outcome in terms of less relapse and decreased TRM and increased 
overall survival. Given that γδ T cells reconstitute early after HSCT, graft content of γδ T 
cells is expected to play protective role during HSCT. 
Our results from paper IV suggest that the TCR repertoire composition of infused γδ T cells 
in terms of occupied homeostatic space, spectratyping, and V and J segment usage, as well as 
bias in V-J pairing frequencies could be more significant than the quantity of γδ T cells per se 
in the graft. This again highlights the need of full qualitative characterization of γδ T cells in 
grafts. 
The amino acid sequences that were exclusively enriched in grafts given to non-relapsed 
patients are most probably of the semi-invariant Vγ9Vδ2 cells. Although we have not 
analyzed the TRD repertoire in this study, it has been shown previously that Vδ2 exclusively 
utilize the Vγ9-JγP pairing segment, suggesting a favorable role of certain Vγ9Vδ2 clones. 
Noteworthy, we showed in paper II that higher graft content of CD27+ γδ T were associated 
with less relapse. Whether this phenotype was preferentially enriched in these CDR3 
sequences is unknown and requires further investigation. 
C 
A B 
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4.3 CHARACTERIZATION OF IN VITRO EXPANDED Vγ9Vδ2 T CELLS FROM 
UCB (PAPER V) 
UCB is an alternative stem cell graft source for allogeneic HSCT and showed outcome 
comparable to other stem cell sources (189). The advantages of UCB as graft source include 
their low content of T cells, permitting less stringent HLA matching with relatively lower risk 
of GVHD. On the other hand, allogeneic HSCT using UCB is associated with prolonged 
neutrophil engraftment time and increased risk of graft failure. Additionally, the added cost of 
collection, HLA typing and storage in biobanks renders UCB transplantation more expensive 
(3). 
In paper V, we used 
aminobisphosphonate (zoledronate) 
and IL-2 at different concentrations to 
optimize a protocol for in vitro 
expansion of UCB Vγ9Vδ2 T cells. 
We showed that cells cultured in 
presence of 5 uM zoledronate and 
(100-200 IU) IL-2/ml showed the 
highest viability and best fold 
expansion after 12 days culture. The 
expanded cells were mainly Vγ9+ and 
Vδ2+, though other immune cell types 
were found such as Vδ1 and NK cells. 
Immunophenotyping showed that the 
majority after expansion were 
differentiated towards central memory 
with upregulated markers such as 
TIM-3, PD-1, CTLA-4 and CD95 
consistent with activation/exhaustion 
phenotype. 
We then addressed whether the TCR 
repertoire of expanded cells was 
altered or skewed. TCR Spectratyping revealed a polyclonal TCR repertoire regardless of the 
culture condition. This suggests that Vγ9Vδ2 cells respond to PAgs in bulk rather than TCR 
clonotypic fashion. We also noticed that most of the V-J recombinations were preserved, 
suggesting that expanded cells retained their baseline TCR repertoire composition and that 
expansion was not skewed towards certain clones. The polyclonal repertoire of expanded 
cells could represent potential limitation as the polyclonal expanded cells might contain 
different functional subsets with different TCR affinities. Therefore, the clinical implication 
of this issue needs to be addressed carefully in future studies. 
 
 
Figure 24. Upper panel,  The results of real-time PCR analysis of 
the gene expression for the cytokines IL-1β, IL-2, IL-6, IL-7, IL-8, 
IL-12, IL-15, and IL-17 in UCB and PB γδ T cells cultured with 5 
μM zoledronate and 200 IU IL-2/ml medium. Lower panel,  
representative FACS plots of the gating strategy for CTV-labeled 
tumor cells (left) and histogram plots of annexin V+ gated cells 
from a control culture (no γδ T cells added), and from cocultures 
with UCB and PB γδ T cells 
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To get more insight into the cytokine profile of UCB Vγ9Vδ2 cells, we used real time PCR to 
quantify several cytokine genes from UCB and PB expanded cells. UCB γδ cells showed 
higher levels of IL-1B, IL-2, and IL-8. Importantly, both UCB and PB showed very low IL-
17 (Figure 24). Finally, we tested their cytotoxic capabilities against cholangiocarcinoma cell 
line and showed that the ability of expanded UCB γδ cells to kill tumor cell lines was 
comparable to PB expanded cells (Figure 24).  
The delayed immune reconstitution is common following UCB transplantation, increasing the 
risk of infections. Furthermore, expansion of γδ T cells post HSCT is dependent on graft type 
and has been shown to be delayed in UCB. 
Adoptive cell therapy (ACT) in the form of donor lymphocyte infusion (DLI) can therefore 
be used to boost immune system. DLI of in vitro expanded γδ T cells would have particular 
significance as their MHC unrestricted feature allows their infusion in large doses with lower 
risk of GVHD. Additionally, γδ T cells from a third-party donor can be an alternative choice 
when the original donor cannot be reached. Given the clinical benefit of early reconstitution 
of γδ T cells, developing a protocol for UCB γδ T expansion is appreciated. 
The expansion of Vγ9Vδ2 cells from PB has been intensively practiced. However, 
extrapolating this method to UCB is challenging. Firstly, γδ T cells account for only smaller 
fraction of T cells in UCB (<1% of lymphocytes) (190). Furthermore, unlike adult PB, UCB 
are dominated by Vδ1 whereas Vδ2 cells represent fewer proportions and are mostly 
functionally immature. Furthermore, It has been reported that UCB Vγ9Vδ2 cells are 
relatively less responsive to PAgs (191). 
Results from paper V highlighted several unique features of in vitro expanded Vγ9Vδ2 cells 
from UCB. Although cells were expanded successfully and the proportions of Vδ2 and Vγ9 
were comparable to those from adult PB, the fold expansion in UCB was remarkably lower 
compared to adult PB expanded cells, reflecting the nature of UCB γδ cells being less 
responsive to PAgs compared to PB. 
Consistent with this finding, it has been shown that neonatal Vδ2 preferentially utilize the Jδ3 
segment (192) whereas in adults Jδ1 is mostly used by Vδ2 (193). The Vδ2-Jδ3 regions was 
found to be enriched in hydrophobic amino acid residues at position 5 that are required for 
PAgs responsiveness (194). 
Another explanation could be that UCB samples were cryopreserved at the time of expansion 
while fresh PB samples from healthy donors were used. Since monocytes APCs are required 
for PAgs presentation (195), it is conceivable that their presenting efficiency could be 
influenced by freezing/thawing process. The use of fresh UCB for expansion of Vγ9Vδ2 cells 
should be investigated to reveal this. 
To compensate for these limitations, additional cytokines such as IL-7, IL-15 and IL-18 need 
to be investigated either alone or in combination with IL-2. The use of these cytokines has 
been shown to enhance proliferation and cytotoxic function of γδ T cells (196). Furthermore, 
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the availability of these cytokines in clinical grade would facilitate their use in ACT. 
Additionally, the use of substances such as ascorbic acid (vitamin C) has been investigated in 
PB γδ T cells and showed enhanced proliferation and effector functions of γδ T cells (197). 
Therefore, investigating these substances in UCB could hold promising results. 
Importantly, cytokine data provided in this study should be carefully interpreted as Vγ9Vδ2 
cells were not sorted before real time PCR.  Given that γδ T cells expanded from UCB 
contained some Vδ1 and NK cells, the exact source of these cytokines is not confirmed. 
Therefore, the pro-inflammatory cytokine profile of UCB expanded cells should be 
confirmed at single cell level. If confirmed, further investigations are required to alleviate 
their functional implications.  
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5 CONCLUDING REMARKS 
Allogeneic HSCT is potentially curative for several disorders. Nevertheless, it is associated 
with several complications. Better understanding of the role of different immune cells 
especially γδ T cells can provide novel therapeutic strategies. 
Monitoring TREC, KREC and TL in allogeneic HSCT patients allowed better understanding 
of the impact of different transplant related factors on adaptive immune reconstitution. Using 
these markers in the allogeneic HSCT setting could help identifying patients at higher risk for 
subsequent morbidity and mortality and could enable individualized treatment plans. 
Results of TREC and KREC should be interpreted carefully as the level of these excision 
circles could be altered by other factors such as degradation, apoptosis or longevity of naïve 
cells. 
CMV reactivation, primary malignant relapse and GVHD represent the main causes of 
transplant related morbidity and mortality following allogeneic HSCT. Though clinically 
distinct events, a complex relation between these events exists. The underpinning 
immunological background is still unclear and represents an interesting topic for ongoing 
research. γδ T cells can be an important player in this context. Reconstitution of γδ T cells 
occur early after HSCT and the protective role of CMV reactive γδ T cells has been described 
both in HSCT and solid organ transplantation. However, whether this response is mediated 
through TCR or other receptors remains elusive. 
More efforts are required to identify γδ TCR ligands and to alleviate their mode of 
recognition. 
The immunobiology of CD8+ γδ T cells is poorly known. Their potential role in GVHD must 
be confirmed in future multi-center studies. Furthermore, the immune mechanisms 
underpinning their alloreactive response is yet to be identified. 
Whether CD8 receptors expressed by few γδ T cells paly a costimulatory role analogous to 
the conventional CD8 T cells remains unknown and urges for further investigation to 
alleviate this role and to show whether this function is mediated by CD8αα or CD8αβ 
receptors.  
The role of CD8+γδ T cells in CMV and GVHD should be further investigated and could 
provide an avenue to better understand the complex relation between CMV and GVHD after 
HSCT. 
The pleotropic function of γδ T cells remains an obstacle against exploiting their full 
therapeutic benefits. The combination of immunophenotyping, TCR immunosequencing 
alongside functional assays could help better understanding of the role of different functional 
subsets. 
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The TRG sequences identified in this study might be used for future generation of a γδ TCR 
library that can be used for adoptive immune therapy of AML. 
In vitro expansion of Vγ9Vδ2 cells from UCB is a promising approach that can provide a 
therapeutic potential following UCB HSCT. More studies are warranted to further improve 
the quantity and quality of expanded cells. 
Given the potent anti-tumorous role of Vδ1 cells, more efforts are required to develop and 
optimize large scale protocols for Vδ1 expansion.  
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